

CURRICULUM VITAE
CAITLIN C. MURPHY, PHD, MPH

January 2025

Associate Professor

Department of Health Promotion & Behavioral Sciences
Center for Health Promotion and Prevention Research
UTHealth Houston School of Public Health
7000 Fannin Street, Suite 2618
Houston, TX 77030

Office: (713) 500-9105
Email: caitlin.c.murphy@uth.tmc.edu

EDUCATION

BA, Sociology, College of Arts and Sciences, New York University, New York, NY, 2010

MPH, Health Promotion, UTHealth Houston School of Public Health, Houston, TX, 2011

PhD, Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2016

PROFESSIONAL EXPERIENCE

2021 – present	Associate Professor, Department of Health Promotion & Behavioral Sciences, UTHealth Houston School of Public Health, Houston, TX
2021 – present	Associate Professor (secondary appointment), Department of Epidemiology, UTHealth Houston School of Public Health, Houston, TX
2021 – present	Member, Center for Health Promotion and Prevention Research, UTHealth Houston School of Public Health, Houston, TX
2021 – present	Adjunct Associate Professor, Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
2019 – 2021	Member, Population Sciences & Cancer Control Program, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
2016 – 2021	Assistant Professor, Division of Epidemiology, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX
2016 – 2021	Assistant Professor (secondary appointment), Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
2016 – 2019	Associate Member, Population Sciences & Cancer Control Program, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
2013 – 2016	Predoctoral Fellow, Digestive Disease Epidemiology Training Program (T32DK007634), University of North Carolina at Chapel Hill, Chapel Hill, NC
2011 – 2013	Project Director, Center for Health Promotion and Prevention Research, UTHealth Houston School of Public Health, Houston, TX

2010 – 2011 Senior Research Coordinator, Institute for Cancer Care Excellence, MD Anderson Cancer Center, Houston, TX

HONORS & AWARDS

2023 Finalist, Cancer Grand Challenges, National Cancer Institute/Cancer Research UK
2023 Nominee, Woman Disruptor of the Year, Healio Gastroenterology
2017 Clinical Research Scholar, University of Texas Southwestern Medical Center
2017 AcademyHealth New Investigator Award
2016 Delta Omega, Theta Chapter at the University of North Carolina at Chapel Hill
2013 Promise of One Award, Houston Affiliate of Susan G. Komen for the Cure
2011 State of Texas Merit Grant Recipient, UTHealth Houston School of Public Health
2010 Faculty Prize Award for Outstanding Graduating Seniors, New York University
2010 Presidential Honors Scholar, New York University
2010 Founders Day Award for Outstanding Scholastic Achievement, New York University
2010 Phi Beta Kappa, Beta Chapter of New York

GRANT AND CONTRACT SUPPORT

Active (PI, Subcontract PI, MPI, or Co-PI)

1. U.S. Department of Defense CA240950. PI: Murphy. My role: PI. Title: *PEGASUS: Pregnancy Complications in AYA Cancer Survivors*. Annual salary recovery or effort: 15%. Total direct costs: \$999,924. Project period: 4/1/2025 – 3/31/2029.
2. NIMHD R01MD017999. PI: Rauh-Hain. My role: Subcontract PI. Title: *Health Equity in Fertility Specialty Care Among Cancer Survivors*. Annual salary recovery or effort: 10%. Total direct costs: \$2,025,270. Project period: 9/1/2023 – 8/31/2028.
2. American Cancer Society RSG-21-046. PI: Murphy. My role: PI. Title: *Co-payments and Adherence to Oral Endocrine Therapy in a Safety-net System*. Annual salary recovery or effort: 10%. Total direct costs: \$655,598. Project period: 7/1/2021 – 6/30/2025.
3. NCI R01CA242558. PI: Murphy. My role: PI. Title: *Early Life Exposures and Risk of Young-Onset Colorectal Cancer*. Annual salary recovery or effort: 25%. Total direct costs: \$1,218,890. Project period: 9/1/2019 – 8/31/2025.
4. NCI R01CA229834. PI: Pruitt. My role: Subcontract PI. Title: *Revisiting Prior Cancer as an Exclusion Criterion for Cancer Clinical Trials*. Annual salary recovery or effort: 15%. Total direct costs: \$2,054,970. Project period: 7/1/2018 – 6/30/2025.

Completed (PI, Subcontract PI, MPI, or Co-PI)

1. U.S. Department of Defense W81XWH-19-1-0324. PI: Murphy. My role: PI. Title: *Fertility and Reproductive Outcomes of Adolescent and Young Adult Cancer Survivors in Texas*. Annual salary recovery or effort: 25%. Total direct costs: \$580,648. Project period: 6/1/2019 – 10/31/2024.
2. American Cancer Society RWIA-136937. PI: Murphy. My role: PI. Title: *Racial and Ethnic Disparities in Treatment Patterns Among Young Adults with Cancer*. Annual salary recovery or effort: 10%. Total direct costs: \$75,000. Project period: 10/1/2022 – 9/30/2024.
3. UT Southwestern Center for Patient-Centered Outcomes Research. PI: Murphy. My role: PI. Title: *Patient Experiences with and Adherence to Oral Anticancer Therapies*. Annual salary recovery or

effort: 10%. Total direct costs: \$50,000. Project period: 5/1/2017 – 9/30/2018.

4. AcademyHealth. PI: Murphy. My role: PI. Title: *Patterns of Prescription Medication Use and Polypharmacy among Cancer Survivors*. Annual salary recovery or effort: 10%. Total direct costs: \$75,000. Project period: 1/1/2017 – 12/31/2017.

Completed (Co-Investigator)

1. NCI UM1CA221940. MPI: Tiro/Skinner/Haas/Kamineni. My role: Co-Investigator. Title: *Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations (METRICS)*. Annual salary recovery or effort: 10%. Total direct costs: \$12,785,348. Project period: 4/1/2018 – 3/31/2023.
2. NCI UM1CA222035. MPI: Corley/Chubak/Halm/Kamineni/Schottinger/Skinner. My role: Co-Investigator and Site Lead, Data Acquisition Unit. Title: *Optimizing Colorectal Cancer Screening Precision and Outcomes in Community-based Populations (PRECISE)*. Annual salary recovery or effort: 10%. Total direct costs: \$14,519,940. Project period: 4/1/2018 – 3/31/2023.
3. NIMHD R01MD012565. MPI: Singal/Yopp. My role: Co-Investigator. Title: *Multi-level Factors for Racial/Ethnic and Socioeconomic Disparities in Prognosis of Hepatocellular Carcinoma*. Annual salary recovery or effort: 10%. Total direct costs: \$2,335,107. Project period: 4/1/2018 – 11/30/2022.
4. CPRIT PP160075. PI: Singal. My role: Co-Investigator. Title: *Implementing an Evidence-based Colorectal Cancer Screening Outreach Program*. Annual salary recovery or effort: 10%. Total direct costs: \$1,499,826. Project period: 9/1/2016 – 5/31/2021.
5. Harold C. Simmons Comprehensive Cancer Center. PI: Abrams. My role: Co-investigator. Title: *Dysregulated Mobile Elements as Drivers of Colorectal Cancer*. Annual salary recovery or effort: 10%. Total direct costs: \$150,000. Project period: 3/1/2017 – 2/28/209.
6. NCI U54CA163308-05S1. MPI: Skinner/Halm. My role: Co-Investigator. Title: *National Survey on Oncologist Reimbursement & EHR-based Tools*. Annual salary recovery or effort: 30%. Total direct costs: \$308,357. Project period: 9/1/2016 – 11/30/2017.

PUBLICATIONS (*indicates role as faculty mentor)

Articles in Peer-Reviewed Journals (listed chronologically)

1. **Murphy CC**, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. *Breast Cancer Res Treat* 2012; 134(2):459-78. Epub 2012 Jun 12. doi:10.1007/s10549-012-2114-5. PMID: 22689091. PMCID: PMC3607286.
2. **Murphy CC**, Hofstetter WL, Correa AM, Ajani JA, Komaki RU, Swisher SG. Utilization of surgery in trimodality eligible patients with locally advanced esophageal adenocarcinoma in a non-protocol setting. *Dis Esophagus* 2013; 26(7):708-15. Epub 2013 Jan 25. doi: 10.1111/dote.12019. PMID: 23350713.
3. Carpentier MY, Vernon SW, Bartholomew LK, **Murphy CC**, Bluethmann SM. Receipt of recommended surveillance guidelines among colorectal cancer survivors: a systematic review. *J Cancer Survivor* 2013; 7(3): 464-83. Epub 2013 May 16. doi: 10.1007/s11764-013-0290-x. PMID: 23677524. PMCID: PMC3737369.

4. **Murphy CC**, Correa AM, Ajani JA, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for locally advanced esophageal adenocarcinoma. *J Gastrointest Surg* 2013; 17(8):1359-69. Epub 2013 May 29. doi: 10.1007/s11605-013-2223-4. PMID: 23715646. PMCID: PMC4998180.
5. **Murphy CC**, Incalcaterra JR, Albright HW, Correa AM, Swisher SG, Hofstetter WL. Pretreatment patient comorbidity and tobacco use increases cost and risk of postoperative complications following esophagectomy at a high volume cancer center. *J Oncol Pract* 2013; 9(5):233-9. Epub 2013 July 29. doi: 10.1200/jop.2013.001047. PMID: 23943906.
6. **Murphy CC**, McQueen A, Bartholomew LK, Del Junco DJ, Coan SP, Vernon SW. Factorial validity and invariance of four psychosocial constructs of colorectal cancer screening: does screening experience matter? *Cancer Epidemiol Biomarkers Prev* 2013; 22(12):2295-302. Epub 2013 Sept 20. doi: 10.1158/1055-9965. PMID: 24057575. PMCID: PMC3858498.
7. **Murphy CC**, Vernon SW, Diamond PM, Tiro JA. Competitive testing of health behavior theories: how do benefits, barriers, subjective norm, and intention influence mammography behavior? *Ann Behav Med* 2014; 47:120-9. Epub 2013 July 19. doi: 10.1007/s12160-013-9528-0. PMID: 23868613. PMCID: PMC3941986.
8. **Murphy CC**, Vernon SW, Haddock NM, Anderson ML, Chubak J, Green BB. Longitudinal predictors of colorectal cancer screening among participants in a randomized controlled trial. *Prev Med* 2014; 66:123-30. Epub 2014 June 15. doi: 10.1016/j.ypmed.2014.06.013. PMID: 24937648. PMCID: PMC4209306.
9. **Murphy CC**, Lewis CL, Golin CE, Sandler RS. Underuse of surveillance colonoscopy in patients at increased risk of colorectal cancer. *Am J Gastroenterol* 2015; 110(5):633-41. Epub 2014 Nov 12. doi: 10.1038/ajg.2014.344. PMID: 25384901. PMCID: PMC4422764.
10. **Murphy CC**, Martin CF, Sandler RS. Racial differences in obesity measures and risk of colorectal adenomas in a large screening population. *Nutr Cancer* 2015; 67(1):98-104. Epub 2014 Nov 25. doi: 10.1080/01635581.2015.976316. PMID: 25425186. PMCID: PMC4281505.
11. Bluethmann SM, Vernon SW, Gabriel KP, **Murphy CC**, Bartholomew LK. Taking the next step: a systematic review and meta-analysis of physical activity interventions and behavior change interventions in post-treatment breast cancer survivors. *Breast Cancer Res Treat* 2015; 149(2):331-42. Epub 2015 Jan 3. doi: 10.1007/s10549-014-3255-5. PMID: 25555831. PMCID: PMC4310805.
12. Tiro JA, Sanders J, Shay LA, **Murphy CC**, Hamann H, Bartholomew LK, Carpenter MY, Vernon SW. Validation of self-reported post-treatment mammography surveillance among breast cancer survivors. *Breast Cancer Res Treat* 2015; 151(2):427-34. Epub 2015 Apr 29. doi: 10.1007/s10549-015-3387-2. PMID: 25922083. PMCID: PMC4935542.
13. **Murphy CC**, Harlan LC, Warren JL, Geiger AM. Race and insurance differences in the receipt of adjuvant chemotherapy among stage III colon cancer patients. *J Clin Oncol* 2015; 33(23):2530-6. Epub 2015 July 6. doi: 10.1200/JCO.2015.61.3026. PMID: 26150445. PMCID: PMC4525047.
14. **Murphy CC**, Harlan LC, Lund JL, Lynch CF, Geiger AM. Patterns of colorectal cancer care in the United States: 1990-2010. *J Natl Cancer Inst* 2015; 107(10): pii: djv198. Epub 2015 July 23. doi: 10.1093/jnci/djv198. PMID: 26206950. PMCID: PMC4840367.
15. **Murphy CC**, Sandler RS, Grubbs JM, Johnson MR, Fisher DA. Underuse and overuse of colonoscopy for screening and surveillance in the Veterans Health Administration. *Clin Gastroenterol Hepatol* 2016; 14(3):436-44. Epub 2015 Oct 19. doi: 10.1016/j.cgh.2015.10.008.

PMID: 26492843. PMCID: PMC4761454.

16. Bluethmann SM, **Murphy CC**, Bartholomew LK, Vernon SW. Use of theory in behavior change interventions: an analysis of programs to increase physical activity in post-treatment breast cancer survivors. *Health Educ Behav* 2017; 44(2):245-53. Epub 2016 May 25. doi: 10.1177/1090198116647712. PMID: 27226430. PMCID: PMC5503486.
17. **Murphy CC**, Sandler RS, Sanoff HK, Yang YC, Lund JL, Baron JA. Decrease in incidence of colorectal cancer among individuals 50 years or older following recommendations for population-based screening. *Clin Gastroenterol Hepatol* 2017; 15(6):903-9. Epub 2016 Sept 5. doi: 10.1016/j.cgh.2016.08.037. PMID: 27609707. PMCID: PMC5337450.

Invited commentary by: Kahi CJ. A colorectal cancer moonshot. *Clin Gastroenterol Hepatol* 2017; 15(6):910-12. Epub 2017 Jan 18. doi: 10.1016/j.cgh.2017.01.00. PMID: 28110096.

18. Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, **Murphy C**, McCallister K, Singal AG. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. *Hepatology* 2017; 65(4):1196-1205. Epub 2016 Oct 24. doi: 10.1002/hep/28895. PMID: 27775821. PMCID: PMC5659110.
19. **Murphy CC**, Yang YC, Shaheen NJ, Hofstetter WL, Sandler RS. An age-period-cohort analysis of obesity and incident esophageal adenocarcinoma among white males. *Dis Esophagus* 2017; 30(3):1-8. Epub 2016 Nov 9. doi: 10.1111/dote.12526. PMID: 27862652. PMCID: PMC5386785.
20. **Murphy CC**, Sanoff HK, Stitzenberg KB, Lund JL, Baron JA, Sandler RS. Patterns of sociodemographic and clinicopathologic characteristics of stages II and III colorectal cancer patients by age: examining potential mechanisms of young-onset disease. *J Cancer Epidemiol* 2017; 2017:4024580. Epub 2017 Jan 23. doi: 10.1155/2017/4024580. PMID: 28239395. PMCID: PMC6440264.
21. **Murphy CC**, Tiro JA, Jean GW, Balasubramanian B, Alvarez CA. High initiation of adjuvant hormonal therapy among uninsured stages I-III breast cancer patients treated in a safety-net system. *J Womens Health (Larchmt)* 2017; 26(6):655-61. Epub 2017 March 15. doi: 10.1089/jwh.2016.609. PMID: 28296574. PMCID: PMC5512308.
22. **Murphy CC**, Lund JL, Sandler RS. Young-onset colorectal cancer: earlier diagnoses or increasing disease burden? *Gastroenterology* 2017; 152(8):1809-12. Epub 2017 Apr 28. doi: 1053/j.gastro.2017.04.03. PMID: 28461196. PMCID: PMC5646667.
23. Bluethmann SM, **Murphy CC**, Tiro JA, Vernon SW, Bartholomew LK. Deconstructing decisions to initiate, maintain or discontinue adjuvant hormonal therapy in breast cancer survivors: a mixed-methods study. *Oncol Nurs Forum* 2017; 44(3): E101-E110. Epub 2017 May 1. doi: 10.1188/17.ONF.E101-E110. PMID: 28635973. PMCID: PMC5507080.
24. Naveed M, Clary M, Ahn C, Kubiliun N, Agrawal D, Cryer B, **Murphy C**, Singal AG. Accuracy of referring provider and endoscopist impression of colonoscopy indication. *J Natl Compr Canc Netw* 2017; 15(7):920-5. Epub 2017 July 1. doi: 10.6004/jnccn.2017.0123. PMID: 28687580.
25. Singal AG, Gupta S, Skinner CS, Ahn C, Santini NO, Agrawal D, Mayorga CA, **Murphy C**, Tiro JA, McCallister K, Tiro JA, Sanders JM, Bishop WP, Loewen AC, Halm EA. Effect of colonoscopy outreach vs. fecal immunochemical test outreach on colorectal cancer screening completion: a randomized clinical trial. *JAMA* 2017; 318(9):806-15. Epub 2017 Sept 5. doi: 10.1001/jama.2017.1138. PMID: 28873161. PMCID: PMC5648645.

Invited commentary by: Pignone M, Miller DP. Using outreach to improve colorectal cancer

screening. *JAMA* 2017; 318(9):799-800. doi: 10.1001/jama.2017.10606. PMID: 28873142.

26. Mokdad AA, **Murphy CC**, Pruitt SL, Mansour JC, Marrero JA, Singal AG, Yopp AC. Effect of hospital safety-net status on treatment use and outcomes in hepatocellular carcinoma. *Cancer* 2018; 124(4):743-51. Epub 2017 Oct 26. doi: 10.1002/cncr.31066. PMID: 29070773.

27. **Murphy CC**, Gerber DE, Pruitt SL. Prior cancer among persons newly diagnosed with cancer: an initial report from the Surveillance, Epidemiology, and End Results program. *JAMA Oncol* 2018; 4(6):832-6. Epub 2017 Nov 22. doi: 10.1001/jamaoncol.2017.3605. PMID: 29167866. PMCID: PMC6370034.

Invited commentary by: Davidson NE. Incident cancer in cancer survivors—when cancer lurks in the background. *JAMA Oncol* 2018; 4(6):836-7. Epub 2012 Nov 22. doi: 10.1001/jamaoncol.2017.4167. PMID: 29167860.

Selected media coverage: Jane E. Brody. When cancer strikes twice. *New York Times*. December 26, 2017. https://www.nytimes.com/2017/12/25/well/when-cancer-strikes-twice.html?_r=0

28. **Murphy CC**, Sigel BM, Yang E, Skinner CS, Halm EA, Gupta S, Sanders JM, McCallister K, Singal AG. Proportion of time covered to measure adherence to colorectal cancer screening. *Gastrointest Endosc* 2018; 88(22):323-31. Epub 2018 Feb 22. doi: 10.1016/j.gie.2018.02.023. PMID: 29477302. PMCID: PMC6050149.

Invited commentary by: Anderson JC, Robertson DJ. Monitoring compliance with colorectal cancer screening: do we have it covered? *Gastrointest Endosc* 2018; 88(2):332-4. doi: 10.1016/j.gie.2018.04.011. PMID: 30012412.

29. **Murphy CC**, Fullington HM, Alvarez CA, Betts AC, Lee SJC, Haggstrom DA, Halm EA. Polypharmacy and patterns of prescription medication use among cancer survivors. *Cancer* 2018; 124(13):2850-7. Epub 2018 Apr 12. doi: 10.1002/cncr.31389. PMID: 29645083. PMCID: PMC6147245.

30. **Murphy CC**, Singal AG. Establishing a research agenda for early-onset colorectal cancer. *PLoS Med* 2018; 15(6):e1002577. doi: 10.1371/journal.pmed.1002577. PMID: 29856736. PMCID: PMC5983407.

Selected media coverage: "Rehabilitative Medicine." *Doctor Radio*. Sirius XM, June 26, 2018.

31. Rich NE, Hester C, Odewole M, **Murphy CC**, Parikh ND, Marrero JA, Yopp YC, Singal AG. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2019; 17(3):551-9. Epub 2018 May 31. doi: 10.1016/j.cgh.2018.05.039. PMID: 29859983. PMCID: PMC6274621.

32. Singal AG, Tiro JA, **Murphy CC**, Marrero JA, McCallister K, Fullington H, Mejias C, Waljee AK, Bishop WP, Santini NO, Halm EA. Mailed outreach invitations significantly improve HCC screening rates in patients with cirrhosis: a randomized clinical trial. *Hepatology* 2019; 69(1):121-30. Epub 2018 Aug 2. doi: 10.1002/hep.30129. PMID: 30070379. PMCID: PMC6324997.

33. Liang P, Allison J, Ladabaum U, Martinez ME, **Murphy CC**, Schoen RE, Shaukat A, Timmouthing J, Gupta S. Potential intended and unintended consequences of recommending initiation of colorectal cancer screening at age 45 years. *Gastroenterology* 2018; 155(4): 950-4. Epub 2018 Aug 20. doi: 10.1053/j.gastro.2018.08.019. PMID: 30138614.

34. **Murphy CC**, Singal AG, Baron JA, Sandler RS. Decrease in incidence of young-onset colorectal cancer before recent increase. *Gastroenterology* 2018; 155(6):1716-19. Epub 2018 Aug 28. doi:

10.1053/j.gastro.2018.07.045. PMID: 30165046. PMCID: PMC6279567.

35. Garcia S, Pruitt SL, Singal AG, **Murphy CC***. Colorectal cancer incidence among Hispanics and non-Hispanic whites in the United States. *Cancer Cause Control* 2018; 29(11):1039-46. Epub 2018 Aug 28. doi: 10.1007/s10552-018-1077-1. PMID: 30155605. PMCID: PMC6628724.

36. Wheeler SB, Spencer JC, Pinheiro LC, **Murphy CC**, Earp J, Carey L, Olshan A, Tse J, Bell ME, Weinberger M, Reeder-Hayes KE. Endocrine therapy non-adherence and discontinuation in Black versus White women. *J Natl Cancer Inst* 2019; 111(5):498-508. Epub 2018 Sept 20. doi: 10.1093/jnci/djy136. PMID: 30239824. PMCID: PMC6510227.

37. Peery AF, Crockett SD, **Murphy CC**, Lund JL, Dallon ES, Williams JL, Jensen ET, Shaheen NJ, Barritt AS, Lieber SR, Kocher B, Barnes EL, Fan YC, Baron TH, Galanko J, Sandler RS. Burden and cost of gastrointestinal, liver and pancreatic diseases in the United States: Update 2018. *Gastroenterology* 2019; 156(1):254-72. Epub 2018 Oct 10. doi: 10.1053/j.gastro.2018.08.063. PMID: 30315778. PMCID: PMC6689327.

38. **Murphy CC**, Yang YC. Use of age-period-cohort analysis in cancer epidemiology research. *Curr Epidemiol Rep* 2018; 5(4):418-31. Epub 2018 Oct 3. doi: 10.1007/s40471-018-0174-8. PMID: 31011507. PMCID: PMC6474378.

39. Magrath M, Yang E, Ahn C, Mayorga CA, Gopal P, **Murphy CC**, Gupta S, Agrawal D, Halm EA, Skinner CS, Singal AG. Impact of a clinical decision support system on guideline adherence of surveillance recommendations for colonoscopy after polypectomy. *J Natl Compr Canc Netw* 2018; 16(11):1321-38. doi: 10.6004/jnccn.2018.7050. PMID: 30442733. PMCID: PMC7210781.

40. **Murphy CC**, Ahn C, Pruitt SL, Hughes AE, Halm EA, Gupta S, Santini NO, McCallister K, Sanders JM, Singal AG, Skinner CS. Screening initiation with FIT or colonoscopy: post-hoc analysis of a pragmatic, randomized trial. *Prev Med* 2019; 118:332-5. Epub 2018 Nov 30. doi: 10.1016/j.ypmed.2018.11.020. PMID: 30508552. PMCID: PMC6362977.

41. **Murphy CC**, Wallace K, Sandler RS, Baron JA. Racial disparities in the incidence of young-onset colorectal cancer and patient survival. *Gastroenterology* 2019; 156(4):958-65. Epub 2018 Dec 3. doi: 10.1053/j.gastro.2018.11.060. PMID: 30521807. PMCID: PMC6409160.

Invited commentary by: Martinez ME, Murphy JD, Gomez SL. Black-white disparities in young-onset colorectal cancer: understanding complexity in reported differences. *Gastroenterology* 2019. Epub 2019 Feb 15. doi: 10.1053/j.gastro.2019.02.01. PMID: 30776345.

42. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld J, John B, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Modi A, Flores A, Satapathy S, Wong R, Huang A, Misra S, Schwartz M, Haste P, Mitrani R, Ho C, Sharma S, Dao A, Nelson K, Delarosa K, Rahim U, Mayuram M, Zie JJ, **Murphy CC†**, Parikh ND‡. Direct-acting antiviral therapy is not associated with HCC recurrence: a multicenter North American cohort study. *Gastroenterology* 2019; 156(6):1683-92. Epub 2019 Jan 17. doi: 10.1053/j.gastro.2019.01.027. PMID: 30660729. PMCID: PMC6598433. †co-senior authors

Invited commentary by: Nault J, Nahon P. Can we move on from the discussion of direct antiviral agents and risk of hepatocellular carcinoma recurrence? *Gastroenterology* 2019; 156(6):1558-60. Epub 2019 Mar 26. doi: 10.1053/j.gastro.2019.03.02 PMID: 30926345.

43. Rich NE, Singal AG, **Murphy CC***. Hepatocellular carcinoma incidence is decreasing among

younger adults in the United States. *Clin Gastroenterol Hepatol* 2020; 18(1):242-8. Epub 2019 Apr 28. doi: 10.1016/j.cgh.2019.04.043. PMID: 31042582. PMCID: PMC6817412.

44. Tavakkoli A, Singal AG, Waljee AK, Scheiman JM, **Murphy CC**, Pruitt SL, Xuan L, Kwon RS, Law RJ, Elta GH, Wright-Slaughter P, Valley TS, Kubilium N, Nathan H, Rubenstein JH, Elmunzer BJ. Regional and racial variations in the utilization of endoscopic retrograde cholangiopancreatography among pancreatic cancer patients in the United States. *Cancer Med* 2019; 8(7):3420-7. Epub 2019 May 14. doi: 10.1002/cam4.2225. PMID: 31087545. PMCID: PMC6601581.
45. **Murphy CC**. Colorectal cancer in the young: does screening make sense? *Curr Gastroenterol Rep* 2019; 21(7):28. Epub 26 May 2019. doi: 10.1007/s11894-019-0695-4. PMID: 31098760. PMCID: PMC6657498.
46. Lee SJC, **Murphy CC**, Geiger AM, Gerber DE, Cox JV, Nair R, Skinner CS. A conceptual model for accrual to cancer clinical trials. *J Clin Oncol* 2019; 37(23):1993-6. Epub 2019 June 5. doi: 10.1200/JCO.19.00101. PMID: 31166822. PMCID: PMC6879309.
47. Tavakkoli A, Singal AG, Waljee AK, Elmunzer E, Pruitt SL, McKey T, Rubenstein JH, Scheiman JM, **Murphy CC***. Racial and geographic disparities in pancreatic cancer incidence and mortality in the United States. *Clin Gastroenterol Hepatol* 2020; 18(1):171-8. Epub 2019 June 13. doi: 10.1016/j.cgh.2019.05.059. PMID: 31202981.
48. **Murphy CC**, Lee SJC, Gerber DE, Cox JO, Fullington HM, Higashi RT. Patient and provider perspectives on delivery of oral cancer therapies. *Patient Educ Couns* 2019; 102(11):2102-9. Epub 2019 June 20. doi: 10.1016/j.pec.2019.06.019. PMID: 31239181. PMCID: PMC6777994.
49. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld J, John B, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Modi A, Flores A, Satapathy S, Wong R, Huang A, Misra S, Schwartz M, Haste P, Mitrani R, Ho C, Sharma S, Dao A, Nelson K, Delarosa K, Rahim U, Mayuram M, Zie JJ, Parikh ND‡, **Murphy CC**‡. Direct-acting antiviral therapy for HCV infection is associated with increased survival in patients with a history of hepatocellular carcinoma. *Gastroenterology* 2019; 157(5):1253-63. Epub 2019 July 30. doi: 10.1053/j.gastro.2019.07.040. PMID: 31374215. PMCID: PMC6815711. ‡co-senior authors
50. Stoffel EM, **Murphy CC**. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. *Gastroenterology* 2020; 18(1):171-8. Epub 2019 Aug 5. doi: 10.1053/j.gastro.2019.07.055. PMID: 31394082. PMCID: PMC6957715.
51. Dharwadkar P, Greenan G, Singal AG, **Murphy CC***. Is colorectal cancer in patients younger than 50 years the same disease as in older patients? *Clin Gastroenterol Hepatol* 2021; 19(1):1920194. Epub 2019 Oct 25. doi: 10.1016/j.cgh.2019.10.028. PMID: 31669054.
52. **Murphy CC**, Sen A, Watson B, Gupta S, Mayo H, Singal AG. A systematic review of repeat fecal occult blood tests for colorectal cancer screening. *Cancer Epidemiol Biomarkers Prev* 2020; 29(2):278-87. Epub 2019 Nov 28. doi: 10.1158/1055-9965.EPI-19-077. PMID: 31740521. PMCID: PMC7007334.
53. **Murphy CC**, Lee SJC, Geiger AM, Cox JV, Ahn C, Nair R, Gerber DE, Halm EA, McCallister K, Skinner CS. A randomized trial of mail and email recruitment strategies for a physician survey on clinical trial accrual. *BMC Med Res Method* 2020 (1):123. Epub 2020 May 19. doi: 10.1186/s12874-020-01014-x. PMID: 32429848. PMCID: PMC7236338.

54. Murphy CC, Skinner CS, Halm EA, Balasubramanian BA, Singal AG. Challenges and approaches to measuring repeat fecal immunochemical test for colorectal cancer screening. *Cancer Epidemiol Biomarkers Prev* 2020; 29(8):1557-1563. Epub 2020 May 26. doi: 10.1158/1055-9965.EPI-20-0230. PMID: 32457184. PMCID: PMC7416474.

55. Faqih A, Singal AG, Fullington HM, Hewitt B, Burstein E, Gopal P, Wylie A, Abrams J, Murphy CC*. Colorectal neoplasia among patients with and without human immunodeficiency virus. *Cancer Epidemiol Biomarkers Prev* 2020; 29(8):1689-1691. Epub 2020 May 28. doi: 10.1158/1055-9965.EPI-20-0021. PMID: 32467350. PMCID: PMC7415639.

56. Chubak J, Anderson M, Jackson M, Murphy CC, Cook A, Green BB. Methodological considerations in calculating and analyzing proportion of time covered as a measure of longitudinal cancer screening adherence. *Cancer Epidemiol Biomarkers Prev* 2020; 29(8):1549-1556. Epub 2020 May 28. doi: 10.1158/1055-9965.EPI-20-0388. PMID: 32467346. PMCID: PMC7415680.

57. Tavakkoli A, Elmunzer BJ, Waljee AK, Murphy CC, Pruitt SL, Huang C, Zhu H, Rong R, Kwon RS, Scheiman JM, Rubenstein JH, Singal AG. Survival analysis among unresectable pancreatic adenocarcinoma patients undergoing endoscopic or percutaneous interventions. *Gastrointest Endosc* 2021; 93(1):154-162. Epub 2020 June 9. doi: 10.1016/j.gie.2020.05.061. PMID: 32531402. PMCID: PMC8786308.

58. Rich NE, Murphy CC*, Yopp AC, Tiro JA, Marrero JA, Singal AG. Sex disparities in presentation and prognosis of 1,110 patients with hepatocellular carcinoma. *Aliment Pharmacol Ther* 2020; 52(4):701-709. Epub 2020 June 29. doi: 10.1111/apt.15917. PMID: 32598091. PMCID: PMC7655123.

59. Singal AG, Tiro JA, Murphy CC, Blackwell JM, Kramer JR, Khan A, Liu J, Zhang S, Phillips J, Hernaez J. Patient-reported barriers are associated with HCC surveillance receipt in a multi-center cohort of patients with cirrhosis. *Clin Gastroenterol Hepatol* 2021; 19(5):987-995. Epub 2020 Jul 3. doi: 10.1016/j.cgh.2020.06.049. PMID: 32629122. PMCID: PMC7779689.

60. Jetelina KK, Carr C, Murphy CC, Sadeghi N, Lea J, Tiro JA. The impact of intimate partner violence on breast and cervical cancer survivors in an integrated, safety-net setting. *J Cancer Surviv* 2020; 14(6):906-914. Epub 2020 Jul 15. doi: 10.1007/s11764-020-00902-x. PMID: 32671556.

61. Kolb JM, Han S, Scott FI, Murphy CC, Hosokawa P, Wani S. Early-onset esophageal adenocarcinoma presents with advanced stage disease but has improved survival compared with older individuals. *Gastroenterology* 2020; 159(6):2238-2240. Epub 2020 Aug 7. doi: 10.1053/j.gastro.2020.08.00. PMID: 32777286. PMCID: PMC9440641.

62. Sanford NN, Dharwadkar P, Murphy CC*. Early-onset colorectal cancer: more than two sides to the story? *Colorectal Cancer* 2020; 9(3):CRC28. Epub 2020 Oct 19. doi: 10.2217/crc-2020-0016.

63. Abualkhair WH, Zhou M, Ochoa CO, Lacayo L, Murphy C, Wu XC, Karlitz JJ. Geographic and intra-racial disparities in early-onset colorectal cancer in the SEER 18 registries of the United States. *Cancer Med* 2020; 9(23):9150-9159. Epub 2020 Oct 22. doi: 10.1002/cam4.3488. PMID: 33094553. PMCID: PMC7724480.

64. Han S, Kolb, JM, Hosokawa P, Friedman C, Fox C, Scott FI, Lieu C, Vajravelu RK, McCarter M, Murphy CC, Cook MB, Gleisner A, Falk GW, Katzka DA, Wani S. The volume-outcome effect calls for centralization of care in esophageal adenocarcinoma: results from a large national cancer registry. *Am J Gastroenterol* 2020; 116(4):811-815. Epub 2020 Nov 23. doi:

10.14309/ajg.0000000000001046. PMID: 33229980.

65. Desai N, Riche NE, Jan MK, Perrman P, McBryde J, Blackwell JM, Quirk L, Clark C, **Murphy CC**, Villarreal D, Waljee A, Gopal P, Singal AG. Randomized clinical trial of inreach with or without mailed outreach to promote hepatitis C screening in a difficult-to-reach patient population. *Am J Gastroenterol* 2021; 116(5):976-983. Epub 2020 Dec 17. doi: 10.14309/ajg.0000000000001085. PMID: 33337657.

66. Dharwadkar P, Greenan G, Stoffel EM, Burstein E, Pirzadeh-Miller S, Lahiri S, Mauer C, Singal AG, **Murphy CC***. Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer. *Clin Gastroenterol Hepatol* 2022; 20(2):353-361. Epub 2020 Dec 24. doi: 10.1016/j.cgh.2020.12.025. PMID: 33359728. PMCID: PMC8222407.

67. Demb J, Liu L, **Murphy CC***, Doubeni CA, Martinez ME, Gupta S. Young-onset colorectal cancer risk among individuals with iron deficiency anemia and hematochezia. *Gut* 2020. Epub 2020 Dec 18. doi: 10.1136/gutjnl-2020-321849. PMID: 33443020. PMCID: PMC8284839.

68. **Murphy CC**, Lupo PJ, Roth M, Winick N, Pruitt SL. Disparities in cancer survival among adolescents and young adults: a population-based study of 88,000 patients. *J Natl Cancer Inst* 2021; 113(8):1074-1083. Epub 2021 Jan 23. doi: 10.1093/jnci/djab006. PMID: 33484568. PMCID: PMC8328976.

Selected media coverage: "Texas Standard." KERA. National Public Radio, April 28, 2021.

69. Lee SJC, **Murphy CC**, Gerber DE, Geiger AM, Halm EA, Nair RG, Cox JV, Tiro JA, Skinner CS. Reimbursement matters: overcoming barriers to clinical trial accrual. *Med Care* 2021; 59(5):461-466. Epub 2021 Jan 22. doi: 10.1097/MLR.0000000000001509. PMID: 33492049. PMCID: PMC8026490.

70. Pruitt SL, Zhu H, Heitjan DF, Rahimi A, Maddineni B, Tavakkoli A, Halm EA, Gerber DE, Xiong D, **Murphy CC**. Survival of women diagnosed with breast cancer and who have survived a previous cancer. *Breast Cancer Res Treat* 2021; 187(3):853-865. Epub 2021 Feb 23. doi: 10.1007/s10549-021-06122-w. PMID: 33620590. PMCID: PMC8318112.

71. Vernon SW, del Junco DJ, Coan SP, **Murphy CC**, Walters ST, Friedman RH, Bastian LA, Fisher DA, Lairson DR, Myers RE. A stepped randomized trial to promote colorectal cancer screening in a nationwide sample of U.S. veterans. *Contemp Clin Trials* 2021; 105:106392. Epub 2021 Apr 3. doi: 10.1016/j.cct.2021.106392. PMID: 33823295. PMCID: PMC8172445.

72. Sapena V, Enea M, Torres F, Celsa C, Rios J, Emanuele G, Rizzo M, Nahon P, Marino Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu M, Tsai P, Jean K, El Kassas M, Shousha HI, Abdelaziz AO, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, **Murphy C**, Kohla M, Masetti C, Dufour J, Merchant N, Cavelletto L, Chemello L, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Camma C, Bruix J, Cabibbo G, Reig M. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. *Gut* 2022; 71(3):595-604. Epub 2021 Mar 19. doi: 10.1136/gutjnl-2020-323663. PMID: 33741640.

73. Pruitt SL, Gerber DE, Zhu H, Heitjan DF, Maddineni B, Xiong D, Singal AG, Tavakkoli A, Halm EA, **Murphy CC**. Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer. *Cancer Medicine* 2021; 10(14):4762-4767. Epub 2021 June 30. doi: 10.1002/cam4.4036. PMID: 34190429. PMCID: PMC8290226.

74. **Murphy CC**, Fullington HM, Gerber DE, Bowman IA, Puligandla M, Dutcher JP, DiPaola RS, Haas NB. Adherence to oral therapies among patients with renal cell carcinoma: post hoc

analysis of the ECOG-ACRIN E2805 trial. *Cancer Med* 2021; 10(17):5917-5924. Epub 2021 Aug 18. doi: 10.1002/cam4.4140. PMID: 34405965. PMCID: PMC8419781.

75. **Murphy CC**, Cirillo PM, Krigbaum NY, Singal AG, Lee M, Zaki T, Burstein E, Cohn BA. Maternal obesity, pregnancy weight gain, and birth weight and risk of colorectal cancer. *Gut* 2022; 71(7):1332-1339. Epub 2021 Aug 24. doi: 10.1136/gutjnl-2021-325001. PMID: 34429385. PMCID: PMC8866526.

Selected media coverage: Maternal health may play a big role in who gets colorectal cancer. KPRC-TV Houston. September 10, 2021.
<https://www.click2houston.com/news/local/2021/09/11/maternal-health-may-play-a-big-role-in-who-gets-colorectal-cancer/>

Cassandra Willyard. The colon cancer conundrum. *Scientific American*. December 1, 2021; S12. <https://www.scientificamerican.com/article/the-colon-cancer-conundrum/>

76. Lee JK, Merchant SA, Jensen CD, **Murphy CC**, Udaltssova N, Corley DA. Rising early-onset colorectal cancer is not an artifact of increased screening colonoscopy use in a large, diverse healthcare system. *Gastroenterology* 2022; 162(1):325-327. Epub 2021 Sept 20. doi: 10.1053/j.gastro.2021.09.034. PMID: 34555382. PMCID: PMC8678196.

77. Peery AF, Crockett SD, **Murphy CC**, Jensen ET, Kim HP, Egberg MD, Lund JL, Moon AW, Pate V, Barnes EL, Schlusser CL, Baron TH, Shaheen NJ, Sandler RS. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2021. *Gastroenterology* 2022; 162(2):621-644. Epub 2021 Oct 19. doi: 10.1053/j.gastro.2021.10.017. PMID: 34678215. PMCID: PMC10756322.

78. Cohn BA‡, Cirillo PM‡, **Murphy CC‡**, Krigbaum NY, Wallace AW. SARS-CoV-2 vaccine protection and deaths among U.S. Veterans during 2021. *Science* 2022; 375(6578):331-336. Epub 2021 Nov 4. doi: 10.1126/science.abm062. PMID: 34735261. PMCID: PMC9836205.
 ‡shared first authors

Selected media coverage: Melissa Healy. Study shows dramatic decline in effectiveness of all three COVID-19 vaccines over time. *Los Angeles Times*. November 4, 2021.
<https://www.latimes.com/science/story/2021-11-04/study-shows-dramatic-decline-in-effectiveness-of-covid-19-vaccines>

Laura McGinley, Lena H. Sun, and Tyler Page. Pfizer-BioNTech expected to seek authorization for coronavirus booster for people 18 and older. *Washington Post*. November 9, 2021. <https://www.washingtonpost.com/health/2021/11/08/pfizer-biontech-coronavirus-booster-authorization-18-and-older/>

79. Zaki T, Singal AG, May FP, **Murphy CC***. Increasing incidence rates of colorectal cancer at age 50-54 years. *Gastroenterology* 2022; 162(3):964-965. Epub 2021 Oct 29. doi: 10.1053/j.gastro.2021.10.039. PMID: 34757141. PMCID: PMC8881296.

80. **Murphy CC**, Cirillo PM, Krigbaum NY, Cohn BA. In utero exposure to 17 α -hydroxyprogesterone caproate and risk of cancer in offspring. *Am J Obstet Gynecol* 2022; 226(1):132.e1-132.e14. Epub 2021 Nov 9. doi: 10.1016/j.ajog.2021.10.035. PMID: 34767803. PMCID: PMC8748293.

Selected media coverage: Melody Petersen. A drug for pregnant women doesn't work, according to the FDA. A company is selling it anyway. *Los Angeles Times*. February 17, 2022. <https://www.latimes.com/business/story/2022-02-17/makena-covis-premature-birth-pregnant-womens-health>

Editorial Board. FDA should pull ineffective pregnancy drug Makena until we know it works. *Los Angeles Times*. February 24, 2022. <https://www.latimes.com/opinion/story/2022-02-24/editorial-does-this-drug-work-stop-selling-it-until-we-know>

Ariana Eunjung Cha. FDA wants to yank pregnancy drug. Firm argues Black women will suffer. *Washington Post*. October 17, 2022. <https://www.washingtonpost.com/health/2022/10/17/preterm-birth-makena-fda-black-women/>

81. **Murphy CC**, Halm EA, Zaki T, Johnson C, Yekkaluri S, Quirk L, Singal AG. Colorectal cancer screening and yield in a mailed outreach program in a safety-net healthcare system. *Dig Dis Sci* 2022; 67(9):4403-4409. Epub 2021 Nov 20. doi: 10.1007/s10620-021-07313-7. PMID: 34800219. PMCID: PMC8605769.
82. Fudman DI, Singal AG, Cooper MG, Lee M, **Murphy CC***. Prevalence of forceps polypectomy of non-diminutive polyps is substantial but modifiable. *Clin Gastroenterol Hepatol* 2022; 20(7):1508-1515. Epub 2021 Nov 25. doi: 10.1016/j.cgh.2021.11.031. PMID: 34839039. PMCID: PMC9133266.
83. Singal AG, Reddy S, Patel HR, Villarreal D, Khan A, Liu Y, Rich NE, **Murphy CC**, Tiro JA, Kramer JR, Hernaez R. Multi-center randomized clinical trial of a mailed outreach strategy for hepatocellular carcinoma surveillance. *Clin Gastroenterol Hepatol* 2022; 20(12):2818-25.e1. Epub 2021 Dec 10. doi: 10.1016/j.cgh.2021.12.014. PMID: 34902568. PMCID: PMC9184300.
84. Schoenberger H, Rich NE, Jones P, Yekkaluri S, Yopp A, Singal AG, **Multi-Ethnic HCC Cohort Investigators**. Racial and ethnic disparities in barriers to care in patients with hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2023; 21(4):1094-6.e2. Epub 2021 Dec 26. doi: 10.1016/j.cgh.2021.12.027. PMID: 34965448. PMCID: PMC9233716.
85. Betts AC, **Murphy CC***, Shay LA, Balasubramanian BA, Markham C, Allicock A. Polypharmacy and prescription medication use in a population-based sample of adolescent and young adult cancer survivors. *J Cancer Surviv* 2023; 17(4):1149-60. Epub 2022 Jan 8. doi: 10.1007/s11764-021-01161-0. PMID: 34997910. PMCID: PMC10614319.
86. Kapinos KA, Halm EA, **Murphy CC**, Santini NO, Loewen AC, Skinner CS, Singal AG. Cost effectiveness of mailed outreach programs for colorectal cancer screening: analysis of a pragmatic, randomized trial. *Clin Gastroenterol Hepatol* 2022; 20(10):2383-2392. Epub 2022 Feb 3. doi: 10.1016/j.cgh.2022.01.054. PMID: 35144024. PMCID: PMC9357235.
87. Jan J, Osho A, **Murphy CC**, Mazure CM, Singal AG, Rich NE. Gender, age, racial and ethnic disparities in clinical trial enrollment for primary liver cancer. *Gastroenterology* 2022; 163(1):14-20.e2. Epub 2022 Mar 11. doi: 10.1053/j.gastro.2022.03.015. PMID: 35288115. PMCID: PMC9232956.
88. Dharwadkar P, Zaki T, **Murphy CC***. Colorectal cancer in young adults. *Hematol Oncol Clin N Am* 2022; 36(3):449-470. Epub 2022 May 13. doi: 10.1016/j.hoc.2022.02.005. PMID: 35577711. PMCID: PMC9177054.
89. Coronado GD, Dickerson JF, Burnett-Hartman AN, Carethers JM, Lee J, McBurnie MA, **Consortium for Early Onset Colorectal Cancer**. Reduced implementation and completion of average-risk annual FIT colorectal cancer screening in Black patients aged 45-49 years. *Clin Gastroenterol Hepatol* 2023; 21(7):1937-9. Epub 2022 May 26. doi: 10.1016/j.cgh.2022.05.009. PMID: 35644342.
90. Pruitt SL, Tavakkoli A, Zhu H, Heitjan DF, Gerber DE, Singal AG, Halm EA, Beg S, Maddineni B, **Murphy CC**. Survival of cancer survivors with a new pancreatic cancer diagnosis. *Cancer Med*

2023; 12(1):200-12. Epub 2022 June 8. doi: 10.1002/cam4.4903. PMID: 35674139. PMCID: PMC9844592.

91. Liu PH, Singal AG, **Murphy CC***. No increase in colorectal cancer screening in 2019 after American Cancer Society recommends starting screening at age 45. *Clin Gastroenterol Hepatol* 2023; 21(7):1947-9.e2. Epub 2022 June 11. doi: 10.1016/j.cgh.2022.05.030. PMID: 35700888. PMCID: PMC9741661.

92. Zaki TA, Liang PS, May FP, **Murphy CC***. Racial and ethnic disparities in early-onset colorectal cancer survival. *Clin Gastroenterol Hepatol* 2023; 21(2):497-506.e3. Epub 2022 June 16. doi: 10.1016/j.cgh.2022.05.035. PMID: 35716905. PMCID: PMC9835097.

93. Tavakkoli A, Pruitt SL, Hoang AQ, Zhu H, Hughes AE, McKey TA, Elmunzer BJ, Kwon RS, **Murphy CC*†**, Singal AG‡. Ethnic disparities in early-onset gastric cancer: a population-based study in Texas and California. *Cancer Epidemiol Biomarkers Prev* 2022; 31(9):1710-19. Epub 2022 June 22. doi: 10.1158/1055-9965.EPI-22-0210. PMID: 35732290. PMCID: PMC9444918. †co-senior authors

94. Liu PH, Sanford NN, Liang PS, Singal AG, **Murphy CC***. Persistent disparities in colorectal cancer screening: a tell-tale sign for implementing new guidelines in younger adults. *Cancer Epidemiol Biomarkers Prev* 2022; 31(9):1701-9. Epub 2022 June 23. doi: 10.1158/1055-9965.EPI-21-1330. PMID: 35765830. PMCID: PMC9444917.

Invited commentary by: Brawley OW. On the potential for optimizing colorectal screening outcomes. *Cancer Epidemiol Biomarkers Prev* 2022; 31(9):1671-1672. doi: 10.1158/1055-9965.EPI-22-0618. PMID: 36052488.

Selected media coverage: "Internal Medicine." Doctor Radio. Sirius XM. September 26, 2022.

95. Perez M, **Murphy CC**, Pruitt SL, Rashdan S, Rahimi A, Gerber DE. Potential impact of revised NCI eligibility criteria guidance: prior malignancy exclusion in breast cancer clinical trials. *J Natl Compr Canc Netw* 2022; 20(7):792-799.e4. doi: 10.6004/jnccn.2022.7017. PMID: 35830895. PMCID: PMC9906999.

96. **Murphy CC**, Betts AC, Allicock MA, Shay LA, Preston SM, Cohn BA, Lupo PJ, Pruitt SL. Stillbirth after adolescent and young adult cancer: a population-based study. *J Natl Cancer Inst* 2022; 8(114):1674-80. Epub 2022 Aug 27. doi: 10.1093/jnci/djac168. PMID: 36029247. PMCID: PMC9745431.

97. Banegas MP, Dickerson JF, Zheng Z, **Murphy CC**, Tucker-Speeley R, Murphy JD, Yabroff KR. Association of social risk factors with mortality among US adults with a new cancer diagnosis. *JAMA Netw Open* 2022; 5(9):e2233009. Epub 2022 Sep 1. doi: 10.1001/jamanetworkopen.2022.33009. PMID: 36112380. PMCID: PMC9482059.

98. Betts AC, Shay LA, Allicock M, Preston SM, Grimes A, **Murphy CC***. Impacts of the COVID-19 pandemic among a nationally representative sample of adolescent and young adults with a history of cancer in the U.S. *J Adolesc Young Adult Oncol* 2023; 12(3):324-30. Epub 2022 Sep 29. doi: 10.1089/jayao.2022.0045. PMID: 36173754.

99. Betts AC, **Murphy CC***, Shay LA, Balasubramanian BA, Markham C, Roth ME, Allicock M. Polypharmacy and medication nonadherence in a population-based sample of adolescent and young adults with a history of cancer, 2008-2017. *J Cancer Surviv* 2023; 17(6):1688-97. Epub 2022 Nov 8. doi: 10.1007/s11764-022-01274-0. PMID: 36346577. PMCID: PMC10164839.

100. Xie L, Gelfand A, **Murphy CC***, Mathew MS, Atem F, Delclos GL, Messiah S. Prevalence of

polypharmacy and associated adverse outcomes and risk factors among children with asthma in the USA: a cross-sectional study. *BMJ Open* 2022; 12(10):e064708. Epub 2022 Oct 13. doi: 10.1136/bmjopen-2022-064708. PMID: 36229143. PMCID: PMC9562747.

101. Singal AG, Masica A, Esselink K, **Murphy CC**, Dever JA, Reczek A, Bensen M, Mack N, Stutts E, Ridenhour JL, Galt E, Brainerd J, Kopplin N, Yekkaluri S, Rubio C, Anderson S, Jan K, Whitworth N, Wagner J, Allen S, Muthukumar AR, Tiro J. Population-based correlates of COVID-19 infection: an analysis from the DFW COVID-19 Prevalence Study. *PLoS One* 2022; 17(12):e0278335. Epub 2022 Dec 1. doi: 10.1371/journal.pone.0278335. PMID: 36454745. PMCID: PMC9714738.
102. Cavestro Giulia M, Mannucci A, Balaguer F, Hampel H, Kupfer SS, Repici A, Sartore-Bianchi A, Seppälä Toni T, Valentini V, Boland Clement R, Brand RE, Buffart TE, Burke CA, Caccialanza R, Cannizzaro R, Cascinu S, Cersek A, Crosbie EJ, Danese S, Dekker E, DacaAlvarez M, Deni F, Dominguez-Valentin M, Eng C, Goel A, Guillem Josè G, Houwen B, Kahi C, Kalady MF, Kastrinos F, Kühn F, Laghi L, Latchford A, Liska D, Lynch P, Malesci A, Mauri G, Meldolesi E, Møller P, Monahan KJ, Moslein G, **Murphy CC**, Nass K, Ng K, Oliani C, Papaleo E, Patel SG, Puzzono M, Remo A, Ricciardiello L, Ripamonti Carla I, Siena S, Singh SK, Stadler ZK, Stanich PP, Syngal S, Turi S, Urso Emanuele D, Valle L, Vanni Valeria S, Vilar E, Vitellaro M, You Y-QN, Yurgelun MB, Zuppardo Raffaella A, Stoffel EM, on behalf of the Associazione Italiana Familiarità Ereditarietà Tumori, Collaborative Group of the Americas on Inherited Gastrointestinal Cancers, European Hereditary Tumor Group, and International Society for Gastrointestinal Hereditary Tumours. Delphi initiative for early-onset colorectal cancer (DIRECt) international management guidelines. *Clin Gastroenterol Hepatol* 2023; 21(3):581-503.e33. Epub 2022 Dec 19. doi: 10.1016/j.cgh.2022.12.006. PMID: 36549470.
103. Liu PH, Singal AG, **Murphy CC***. Stool-based tests mitigate impacts of COVID-19 on colorectal cancer screening. *Clin Gastroenterol Hepatol* 2023; 21(6):1667-9.e2. Epub 2022 Dec 22. doi: 10.1016/j.cgh.2022.12.014. PMID: 36566814. PMCID: PMC9780015. PMCID: PMC9780015.
104. Meernik C, Jorgensen K, Wu CF, **Murphy CC**, Baker VL, Brady PC, Nitecki R, Nichols HB, Rauh-Hain JA. Disparities in the use of assisted reproductive technologies after breast cancer: a population-based study. *Breast Cancer Res Treat* 2023; 198(1):149-58. Epub 2023 Jan 6. doi: 10.1007/s10549-022-06857-0. PMID: 36607486. PMCID: PMC10184512.
105. Jorgensen K, Meernik C, Wu CF, **Murphy CC**, Baker VL, Jarmon P, Brady PC, Nitecki R, Nichols HB, Rauh-Hain JA. Disparities in fertility-sparing treatment and use of assisted reproductive technology after diagnosis of cervical, ovarian, or endometrial cancer. *Obstet Gynecol* 2023;141(2):341-53. Epub 2023 Jan 4. doi: 10.1097/aog.0000000000005044. PMID: 36649345. PMCID: PMC9858239.
106. **Murphy CC**, Cirillo PM, Krigbaum NY, Singal AG, Zaki T, Jones DP, Cohn BA. In-utero exposure to antibiotics and risk of colorectal cancer in a prospective cohort of 18,000 adult offspring. *Int J Epidemiol* 2023; 52(5):1448-58. Epub 2023 Jan 24. doi: 10.1093/ije/dyad004. PMID: 36692207. PMCID: PMC10555902.
107. **Murphy CC**, Cirillo PM, Krigbaum NY, Singal AG, Cohn BA. In utero exposure to anti-emetic and risk of adult-onset colorectal cancer. *JNCI Cancer Spect* 2023; 7(2):pkad021. Epub 2023 Mar 10. doi: 10.1093/jncics/pkad021. PMID: 36895101. PMCID: PMC10076093.
108. Betts AC, Shay LA, Lupo PJ, Pruitt SL, Roth ME, Allicock MA, Cohn BA, **Murphy CC***. Adverse birth outcomes of adolescent and young adult women diagnosed with cancer during pregnancy. *J*

Natl Cancer Inst 2023; 115(6):619-27. Epub 2023 Mar 13. doi: 10.1093/jnci/djad044. PMID: 36912709. PMCID: PMC10248853.

Invited commentary by: Nathan P, Su HI. Making sense of the risks: what to tell adolescents and young adults diagnosed with cancer during pregnancy. J Natl Cancer Inst 2023; Epub 2023 Apr 11. doi: 10.1093/jnci/djad066. PMID: 37040085.

109. Zaki TA, Ziogas A, Chang J, **Murphy CC***, Anton-Culver H. Survival of Middle Eastern and Northern African individuals diagnosed with colorectal cancer: a population-based study in California. Cancer Epidemiol Biomarkers Prev 2023; 32(6):795-801. Epub 2023 April 3. doi: 10.1158/1055-9965.EPI-22-1326. PMID: 37012208.
110. Rathod AB, **Murphy CC***, Rahimi A, Pruitt SL. Revisiting exclusion of prior cancer in clinical trials of male breast cancer. J Cancer 2023; 14(5):737-40. Epub 2023 Mar 21. doi: 10.7150/jca.80740. PMID: 37056393. PMCID: PMC10088891.
111. **Murphy CC**, Lee JK, Liang PS, May FP, Zaki TA. Declines in colorectal cancer incidence and mortality rates slow among older adults. Clin Gastroenterol Hepatol 2024; 22(2):416-19.e5. Epub 2023 June 10. doi: 10.1016/j.cgh.2023.05.033. PMID: 37308035.
112. **Murphy CC**, Tortolero GA, Gerber DE, Pruitt SL. Prevalence of prior cancer among persons newly diagnosed with cancer: an updated report from the Surveillance, Epidemiology, and End Results program. JAMA Oncol 2023; 9(8):1147-50. Epub 2023 June 15. doi: 10.1001/jamaoncol.2023.1723. PMID: 37318821. PMCID: PMC10273127.
113. Narasimman M, Pruitt SL, **Murphy CC**, Singal AG, Tavakkoli A. Ethnic disparities in early-onset gastric cancer persist across rural-urban geographies. Cancer Epidemiol Biomarkers Prev 2023; 23(9):1169-73. Epub 2023 June 23. doi: 10.1158/1055-9965.EPI-23-0236. PMID: 37352435.
114. Narasimman M, Hernaez R, Cerdá V, Lee M, Sood A, Yekkaluri S, Khan A, Quirk L, Liu Y, Kramer JR, Lee SJC, **Murphy CC**, Tiro JA, Singal AG. Hepatocellular carcinoma surveillance may be associated with potential psychological harms in patients with cirrhosis. Hepatology 2024; 79(1):107-117. Epub 2023 July 4. Doi: 10.1097/HEP.0000000000000528. PMID: 37401857.
115. Narasimman M, Hernaez R, Cerdá V, Lee M, Yekkaluri S, Khan A, Sood A, Gurley T, Quirk L, Liu Y, Kramer JR, Lee SC, Tiro JA, **Murphy CC**, Singal AG. Financial burden of hepatocellular carcinoma screening in patients with cirrhosis. Clin Gastroenterol Hepatol 2024; 22(4):760-7.e1. Epub 2023 Aug 4. doi: 10.1016/j.cgh.2023.07.018. PMID: 37544418.
116. Kopplin N, Garcia A, Recek A, Wilkinson K, Yekkaluri S, **Murphy CC**, Tiro J, Muthukumar AR, Masica A, Singal AG. Post-acute sequelae of COVID-19 and longitudinal antibody levels in a community-based cohort. PLoS One 2023; 18(9): e0291259. Epub 2023 Sept 8. doi: 10.1371/journal.pone.0291259. PMID: 37682916. PMCID: PMC10490864.
117. **Murphy CC**, Betts AC, Pruitt SL, Cohn BA, Shay LA, Allicock MA, Wang JS, Lupo PJ. Birth defects in offspring of adolescents and young adults with a history of cancer: a population-based study of 27,000 women. Cancer Epidemiol Biomarkers Prev 2023; 18(9):e0291259. Epub 2023 Sept 14. doi: 10.1158/1055-9965.EPI-23-0743. PMID: 37707371. PMCID: PMC10842971.
118. **Murphy CC**, Zaki TA. Changing epidemiology of colorectal cancer: birth cohort effects and emerging risk factors. Nat Rev Gastroenterol Hepatol 2024; 21(1):25-34. Epub 2023 Sept 18. doi: 10.1038/s41575-023-00841-9. PMID: 37723270.

119. Liu PH, Singal AG, **Murphy CC***. Colorectal cancer screening receipt does not differ by 10-year mortality risk among older adults. *Am J Gastroenterol* 2024; 119(2):353-56. Epub 2023 Oct 2. doi: 10.14309/ajg.0000000000002536. PMID: 37782288. PMCID: PMC10872814.

120. **Murphy CC**, Wani S, Tavakkoli A, Singal AG. Pandemic-related changes in incidence and mortality rates of gastrointestinal cancers during 2020. *Am J Gastroenterol* 2024; 119(2):382-7. Epub 2023 Oct 4. doi: 10.14309/ajg.0000000000002526. PMID: 37791616. PMCID: PMC10873074.

121. Demb J, Liu L, **Murphy CC***, Doubeni CA, Martinez ME, Gupta S. Time to endoscopy or colonoscopy among adults younger than 50 years old with iron deficiency anemia or hematochezia in the Veterans Health Administration. *JAMA Netw Open* 2023; 6(11):e2341516. doi: 10.1001/jamanetworkopen.2023.41516. PMID: 37930701. PMCID: PMC10628727.

122. Rutter CM, Nascimento de Lima P, Maerzluft CE, May FP, **Murphy CC**. Black-White disparities in colorectal cancer outcomes: a simulation study of screening benefit. *J Natl Cancer Inst Monogr* 2023; 2023(62):196-203. doi: 10.1093/jncimonographs/lqad019. PMID: 37947338. PMCID: PMC10637026.

123. Liu PH, Nair R, Skinner CS, **Murphy CC**, Kim E, Ortiz C, Wang L, Hu E, Lykken J, Levin TR, Green BB, Hahn EE, Halm EA. Unsatisfactory fecal immunochemical tests for colorectal cancer screening: Prevalence, reasons, and subsequent testing. *Cancer Epidemiol Biomarkers Prev* 2024; 33(2):215-23. Epub 2023 Nov 15. doi: 10.1158/1055-9965.EPI-23-0507. PMID: 37964449. PMCID: PMC10873102.

124. Daher D, El Dahan KS, Yekkaluri S, Gopal P, Rich NE, Parkih ND, **Murphy CC**, Singal AG. Proportion of time covered by hepatocellular carcinoma surveillance in patients with cirrhosis. *Am J Gastroenterol* 2023. Epub 2023 Nov 17. doi: 10.14309/ajg.0000000000002596. PMID: 37975606.

125. Gupta S, May FP, Kupfer SS, **Murphy CC**. Birth cohort colorectal cancer: implications for research and practice. *Clin Gastroenterol Hepatol* 2024; 22(3):455-69.e7. Epub 2023 Dec 9. doi: 10.1016/j.cgh.2023.11.040. PMID: 38081492.

Selected media coverage: Knvul Sheikh. More young people than ever will get colorectal cancer this year. *New York Times*. March 27, 2024.
<https://www.nytimes.com/2024/03/27/well/colon-cancer-symptoms-treatment.html>

126. Betts AC, Roth ME, Albritton K, Pruitt SL, Lupo PJ, Shay LA, Allicock M, **Murphy CC***. Racialized inequities in live birth after cancer: a population-based study of 63,000 female adolescents and young adults with cancer. *Cancer* 2024. Epub 2024 May 2. doi: 10.1002/cncr.35341. PMID: 38696087.

127. Singal AG, Narasimman M, Daher D, Yekkaluri S, Liu Y, Lee M, Cerda V, Khan A, Seif El Dahan K, Kramer J, Gopal P, **Murphy C**, Hernaez R. Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomized clinical trial. *Gut* 2024. Epub 2024 June 5. doi: 10.1136/gutjnl-2024-332508. PMID: 38839269.

128. **Murphy CC**, El Dahan KS, Singal AG, Cirillo PM, Krigbaum NY, Cohn BA. In utero exposure to antihistamines and risk of hepatocellular carcinoma in a multi-generational cohort. *Hepatol Commun* 2024; 8(8):e0497. Epub 2024 July 22. doi: 10.1097/HC9.0000000000000497. PMID: 39037384.

129. Tortolero GA, Betts AC, Suragh TA, Pruitt SL, Roth ME, **Murphy CC***. Social vulnerability and survival in 112,000 adolescents and young adults with cancer: a population-based study in

Texas. J Natl Cancer Inst 2024. Epub 2024 Aug 1. doi: 10.1093/jnci/djae170. PMID: 39084675.

130. Liu PH, Pruitt SL, Singal AG, **Murphy CC***. Comparing SEER and NCDB: a case study using colorectal cancer. Cancer Causes Control 2024. Epub 2024 Aug 6. doi: 10.1007/s10552-024-01902-3. PMID: 39105992.
131. Singal AG, Daher D, Narasimman M, Mhi SY, Liu Y, Cerdá V, Banala C, Khan A, Lee M, Seif El Dahan K, **Murphy CC**, Kramer JR, Hernaez R. Benefits and harms of hepatocellular carcinoma screening outreach in patients with cirrhosis: a multi-center randomized clinical trial. J Natl Cancer Inst 2024. Epub 2024 Sept 17. doi: 10.1093/jnci/djae22. PMID: 39288308.
132. Rich NE, Jones PD, Zhu H, Prasad T, Hughes A, Pruitt S, **Murphy CC**, Seif-El-Dahan K, Daher D, Figueroa G, Castaneda S, Quirk L, Gonzales M, Carranza O, Bourque S, Baset N, Yopp AC, Singal AG. Impact of racial, ethnic, and socioeconomic disparities on presentation and survival of HCC: a multicenter study. Hepatol Commun 2024; 8(11):e0477. Epub 2024 Nov 1. doi: 10.1097/HC9.000000000000477. PMID: 39666898. PMCID: PMC11469814.
133. **Murphy CC**, Wang JS, Betts AC, Lupo PJ, Shay LA, Allicock MA, Kirk CL, Pruitt SL. Childbirth after cancer among 42,896 male adolescents and young adults: a population-based study. J Natl Cancer Inst 2025; djae347. Epub 2025 Jan 3. doi: 10.1093/jnci/djae347. PMID: 39752327.

Invited Editorials, Commentaries, and Letters to the Editor (listed chronologically)

1. **Murphy CC**, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Reply to: A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 2013; 138(1):328. Epub 2013 Feb 12. doi: 10.1007/s10549-013-2422-4. PMID: 23400580.
2. **Murphy CC**, Baron JA (invited editorial). Colorectal cancer in older ages: what's ahead? Clin Gastroenterol Hepatol 2017; 15(6):901-2. Epub 2017 Jan 28. doi: 10.1016/j.cgh.2017.01.019. PMID: 28143729.
3. Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, **Murphy C**, McCallister K, Singal AG. HCC surveillance: striving for a better balance of benefits and harms. Hepatology 2017; 66(3):1002-3. Epub 2017 May 24. doi: 10.1002/hep.29286. PMID: 28543272.
4. **Murphy CC**, Sanoff HK, Stitzenberg KB, Baron JA, Sandler RS, Yang YC, Lund JL. Reply to: Colorectal cancer incidence patterns in the United States, 1974—2013. J Natl Cancer Inst 2017; 109(8):dix104. Epub 2017 Aug 2. doi: 10.1093/jnci/dix104. PMID: 29117391. PMCID: PMC6440264.
5. Singal AG, **Murphy CC** (invited editorial). Hepatocellular carcinoma: a roadmap to reduce incidence and future burden. J Natl Cancer Inst 2018; 111(6):527-8. Epub 2018 Dec 13. doi: 10.1093/jnci/djy18. PMID: 30544135. PMCID: PMC6579741.
6. Singal AG, **Murphy CC**. Hepatocellular carcinoma surveillance: an effective but complex process. Gastroenterology 2019; 156(4):1215. Epub 2018 Dec 10. doi: 10.1053/j.gastro.2018.08.066. PMID: 30543799.
7. Singal AG, Parikh ND, **Murphy CC**. Reply to: Did direct-acting antiviral therapy for hepatitis C virus infection really improve the survival of patients with hepatocellular carcinoma? Gastroenterology 2020; 158(6):1844. Epub 2020 Feb 18. doi: 10.1053/j.gastro.2020.02.024. PMID: 32084426.
8. Lee JK, Burnett-Hartman A, **Murphy CC** (invited editorial). Sugary truth of early-onset colorectal

neoplasia – not so sweet after all. *Gastroenterology* 2021; 161(1):27-29. Epub 2021 Apr 24. doi: 10.1053/j.gastro.2021.04.046. PMID: 33905675.

9. **Murphy CC**, Cohn BA. Early life: an important window of susceptibility for colorectal cancer. *Gastroenterology* 2022; 163(2):532-533. Epub 2022 Jan 5. doi: 10.1053/j.gastro.2022.01.003. PMID: 35007514. PMCID: PMC9259754.
10. **Murphy CC‡**, Paskett ED‡, Pruitt SL‡ (invited editorial). The influence of place and geography on outcomes across the cancer continuum. *Gastroenterology* 2022; 163(2):369-371. Epub 2022 Jun 4. doi: 10.1053/j.gastro.2022.06.009. PMID: 35671802. ‡contributed equally
11. Burnett-Hartman AN, **Murphy CC**, Lee JK (invited editorial). Novel, emerging risk factors for colorectal cancer remain understudied. *Gastroenterology* 2022; 163(3):574-576. Epub 2022 Jul 7. doi: 10.1053/j.gastro.2022.06.085. PMID: 35809616.
12. Tavakkoli A, Pruitt SL, **Murphy CC**. Reply to: Cancer progress and priorities: gastric cancer. *Cancer Epidemiol Biomarkers Prev* 2023; 33(9):12870. doi: 10.1158/1055-9965.EPI-23-0409. PMID: 37655426.
13. **Murphy CC**, Cirillo PM, Krigbaum NY, Cohn BA (invited editorial). The colorectal cancer enigma and early life exposures. *Clin Gastroenterol Hepatol* 2023. Epub 2023 Dec 4. doi: 10.1016/j.cgh.2023.11.027. PMID: 38056800.
14. **Murphy CC**, Patel SG, Liang PS, Weiss JM (invited editorial). Disparities in early onset colorectal cancer. *Front Oncol* 2024; 14:1537473. Epub 2024 Dec 19. doi: 10.3389/fonc.2024.1537473. PMID: 39749031. PMCID: PMC11693504.

Non-Peer-Reviewed Articles (listed chronologically)

1. Dwyer AJ, **Murphy CC**, Boland CR, Garcia R, Hampel H, Limburg P, Lowery J, Zauber AG, Waring S, Worrall S, Perea J, Sigel R, Lee J, Molmenti C, Sears CL, Buckhaults P, Hayes R, Hussan H, de Miranda N, Palles C, Diaz L, Song M, Cercek A, Lieu CH, Patel SG, Karlitz JJ, Cao Y, Demb J, Blatchford P, Risendal B, Weltzien E, Wali A, Dascher P, Loomans-Kropp H, Levell CL, Wehling K, Martin J, Pesmen C, Kuchar V, Soisson R, Davis A, Ahnen D. A summary of the Fight Colorectal Cancer working meeting: exploring risk factors and etiology of sporadic early-age onset colorectal cancer. *Gastroenterology* 2019; 157(2):280-8. Epub 2019 May 13. doi: 10.1053/j.gastro.2019.04.049. PMID: 31095950.
2. Lieberman D, Ladabaum U, Brill JV, May FP, Kim L, **Murphy C**, Wender R, Teixeira K. Reducing the burden of colorectal cancer: AGA positions statements. *Gastroenterology* 2022; 163(2):520-526. Epub 2022 June 14. doi: 10.1053/j.gastro.2022.05.011. PMID: 35715380.

Book Chapters (listed chronologically)

1. Vernon SW, **Murphy CC**, McQueen A. Colorectal Cancer Screening. In Holland JC, Breitbart WS, Jacobsen PB, Lederberg MG, Loscalzo MJ, McCorkle R (eds). *Psycho-Oncology*, 3rd edition. New York: Oxford University Press. 2015. ISBN: 9780199363315.
2. **Murphy CC**, Vernon SW. Colorectal Cancer Screening. In Breitbart WS, Butow PN, Jacobsen PB, Lam WWT, Lazenby M, Loscalzo MJ (eds). *Psycho-Oncology*, 4th edition. New York: Oxford University Press. 2021. ISBN: 9780190097653.
3. Patel S, **Murphy CC**, Liu C, Hampel H. Early Age Onset Colorectal Cancer. In Berger F, Boland CR (eds). *Novel Approaches to Colorectal Cancer*, Volume 151 in the *Advances in Cancer Research* series. Cambridge, Massachusetts: Academic Press. 2021. ISBN: 9780128240786.

Submitted Manuscripts Under Review

1. **Murphy CC**, Dias E, Cirillo PM, Krigbaum NY, Cohn BA. Father's occupation linked to harmful exposures and colorectal cancer in his adult offspring.
2. Cohn BA, Cirillo PM, La Merrill MA, **Murphy CC**, Hu X, Krigbaum NY. Grandmaternal perinatal serum polychlorinated biphenyls and prevalence of obesity in adult daughter and granddaughters.
3. Rathod A, **Murphy CC***, Pruitt SL. Risk of second cancer in a population-based sample of 28,000 survivors of early-onset colorectal cancer.
4. Holowatyj AN, Washington MK, Goldberg RM, **Murphy CC**. Birth cohort effects in appendiceal adenocarcinoma incidence across the United States.

SELECTED PEER-REVIEWED CONFERENCE PRESENTATIONS (*indicates role as faculty mentor)

International (listed chronologically)

1. **Murphy CC**, Skinner CS, Halm EA, Sanders JM, Singal AG. Patterns and yield of repeat fecal immunochemical test over four rounds of screening in a safety-net healthcare system. Podium presentation at Digestive Disease Week (DDW) 2018, Washington, DC. June 2018.
2. **Murphy CC**, Skinner CS, Gupta S, Halm EA, Ahn C, Sanders JM, McCallister K, Singal AG. A pragmatic, randomized trial of FIT vs. colonoscopy outreach: patterns of screening initiation by intervention dose. Podium presentation at Digestive Disease Week (DDW) 2018, Washington, DC. June 2018.
3. Singal AG, Rich NE, **Murphy CC[†]**, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld J, John B, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Modi A, Flores A, Satapathy S, Wong R, Huang A, Misra S, Schwartz M, Haste P, Mitrani R, Ho C, Sharma S, Dao A, Nelson K, Delarosa K, Rahim U, Mayuram M, Zie JJ, Parikh ND. Direct-active antiviral therapy significantly reduces early HCC recurrence: a multicenter U.S. cohort study. Podium presentation at The Liver Meeting 2018, San Francisco, CA. November 2018.
4. Dharwadkar P, Greenan G, Singal AG, **Murphy CC***. Genetic counseling and germline testing among patients with young-onset colorectal cancer at a safety-net hospital. Poster presentation (with distinction) at Digestive Disease Week (DDW) 2019, San Diego, CA. May 2019.
5. Tavakkoli A, Singal AG, Waljee AK, Elmunzer J, Pruitt SL, Rubenstein JH, Scheiman JM, **Murphy CC***. Racial and geographic disparities in pancreatic cancer incidence and mortality in the United States. Poster presentation (with distinction) at Digestive Disease Week (DDW) 2019, San Diego, CA. May 2019.
6. Rich NE, Yopp AC, Singal AG, **Murphy CC***. Hepatocellular carcinoma incidence is decreasing among young and middle-aged adults in the United States. Podium presentation at the 13th Annual Meeting of the International Liver Cancer Association (ILCA), Chicago, IL. September 2019.
7. Singal AG, McCallister K, Ortiz C, Kramer J, Zhang S, Liu Y, Rich NE, Tiro JA, Lee SC, **Murphy CC**, Hernandez R. Financial burden is common in U.S. patients with cirrhosis and associated with lower HCC surveillance receipt. Podium presentation at The Liver Meeting 2019, Boston, MA.

November 2019.

8. **Murphy CC**, Cirillo PM, Krigbaum NY, Singal AG, Burstein E, Jones DP, La Hoz R, Cohn BA. In utero exposure to sulfonamide antibiotics and risk of young-onset colorectal cancer. Oral presentation at the 2021 Digestive Disease Week (DDW), Virtual, May 2021.
9. **Murphy CC**, Betts AC. Racial and ethnic disparities in live birth and fetal death among adolescent and young adult women diagnosed with cancer. Oral presentation at the 4th Global Adolescent and Young Adult Cancer Congress, Virtual. December 2021.
10. **Murphy CC**, Cirillo PM, Krigbaum NY, Singal AG, Cohn BA. Infant growth, childhood obesity, and risk of colorectal cancer: a prospective study of 18,000 children. Lecture presentation at Digestive Disease Week (DDW) 2022, San Diego, CA. May 2022.
11. **Murphy CC**, Betts AC, Singal AG, Lupo P, Allicock MA, Shay LA, Preston SM, Pruitt SL. Birth outcomes of young women diagnosed with gastrointestinal cancer. Lecture presentation at Digestive Disease Week (DDW) 2022, San Diego, CA. May 2022.
12. Dharwadkar P, Liu S, Singal AG, **Murphy CC***. Microsatellite instability and mismatch repair testing in early-onset colorectal cancer. Lecture presentation at Digestive Disease Week (DDW) 2022, San Diego, CA. May 2022.
13. Zaki T, May FP, Liang PS, **Murphy CC***. Racial and ethnic disparities in early-onset colorectal cancer survival. Lecture presentation at Digestive Disease Week (DDW) 2022, San Diego, CA. May 2022.
14. Liu PH, Singal AG, **Murphy CC***. Expected 10-year mortality is not associated with colorectal cancer screening. Lecture presentation at Digestive Disease Week (DDW) 2023, Chicago, IL. May 2023.
15. Rathod A, Pruitt SL, **Murphy CC***. Risk of second cancers in a population-based sample of 7,000 survivors of early-onset colorectal cancer. Lecture presentation at Digestive Disease Week (DDW) 2023, Chicago, IL. May 2023.
16. Zaki T, **Murphy CC***. Global increases in incidence rates of colorectal cancer across birth cohorts. Lecture presentation at Digestive Disease Week (DDW) 2023, Chicago, IL. May 2023.
17. **Murphy CC**, Jha S, Cirillo PM, Krigbaum NY, Singal AG, Cohn BA. A prospective study of antibiotic use in childhood and risk of adult-onset colorectal cancer. Lecture presentation at Digestive Disease Week (DDW) 2024, Washington, DC. May 2024.
18. **Murphy CC**, Betts AC, Kirk C, Shay LA, Allicock MA, Pruitt SL. Racial and ethnic disparities in non-cancer mortality among 400,000 adolescents and young adults diagnosed with cancer: a population-based study. Podium presentation at the 6th Global AYA Congress, Melbourne, Australia, December 2024.

National (listed chronologically)

1. **Murphy CC**, Fullington HM, Alvarez CA, Lee SJC, Betts A, Haggstrom DA, Halm EA. Polypharmacy and patterns of prescription medication use among cancer survivors. Podium presentation at the 2018 AcademyHealth Annual Research Meeting, Seattle, WA. June 2018.
2. **Murphy CC**, Cirillo PM, Krigbaum NY, Cohn BA. In utero exposure to 17 α -hydroxyprogesterone caproate may contribute to increasing incidence rates of early-onset cancer. Podium presentation at the 2021 ENDO Meeting, Virtual. March 2021.

3. **Murphy CC**, Cirillo PM, Krigbaum NY, Cohn BA. Gestational growth and risk of young-onset colorectal cancer. Lightning talk at the 45th Annual Meeting of the American Society of Preventive Oncology (ASPO), Virtual. March 2021.
4. **Murphy CC**, Cirillo PM, Krigbaum NY, Cohn BA. In utero exposure to anti-nauseants and risk of young-onset colorectal cancer. Poster presentation at the American Association of Cancer Research (AACR) Annual Meeting 2021, Virtual. April 2021.
5. **Murphy CC**, Betts AC, Allicock A, Shay LA, Preston SM, Lupo PJ, Pruitt SL. Birth outcomes of adolescent and young adult women with cancer in Texas, 1995 – 2016. Oral presentation at the 12th Annual Texas AYA Oncology Conference, Virtual. February 2022.
6. **Murphy CC**, Betts AC, Lupo PJ, Allicock M, Shay LA, Preston SM, Pruitt SL. Risk of fetal death in a population-based sample of 65,000 adolescent and young adult women with a history of cancer. Oral presentation at the 46th Annual Meeting of the American Society of Preventive Oncology (ASPO), Tucson, AZ. March 2022.
7. **Murphy CC**, Betts AC, Lupo PJ, Shay LA, Cohn BA, Allicock MA, Pruitt SL. A population-based study of birth defect in adolescent and young adult women with a history of cancer. Oral presentation at the Society of Epidemiologic Research (SER) 2023 Annual Meeting, Portland, OR. June 2023.
8. Cirillo PM, Krigbaum NY, Keeler C, **Murphy CC**, Cohn BA. Associations of early menarche and adolescent overweight with neighborhood indices of social polarization: evidence from the Child Health and Development Studies. Oral presentation at the Society of Epidemiologic Research (SER) 2023 Annual Meeting, Portland, OR. June 2023.
9. **Murphy CC**, Betts AC, Wang JS, Lupo PJ, Shay LA, Allicock MA, Pruitt SL. Maternal mortality after adolescent and young adult cancer: a population-based study. Oral presentation at the Society of Epidemiology Research (SER) 2024 Annual Meeting, Austin, TX. June 2024.
10. Wang JS, Pruitt SL, **Murphy CC***. Disparities by neighborhood racial and ethnic typology and neighborhood poverty in survival among adolescents and young adults with cancer in Texas. Oral presentation at the Society of Epidemiology Research (SER) 2024 Annual Meeting, Austin, TX. June 2024.
11. Betts AC, Allicock M, Kirk C, Olumba B, Stinnett C, Griffith W, Shay LA, **Murphy CC***. Nothing About Me without Me: Community-Engaged Research. Panel presentation at CancerCON Live Austin, TX. August 2024.

PROFESSIONAL MEMBERSHIP

American Gastroenterological Association
Society for Epidemiologic Research
American Association for Cancer Research
Phi Beta Kappa

TEACHING

Primary Courses Taught

PHD 1498 Cancer Prevention and Control Journal Club (Primary Instructor), UTHealth Houston School of Public Health, Summer 2024 (100%)

PHD 1421	Quantitative Analysis for Behavioral Sciences (Co-Instructor), UTHealth Houston School of Public Health, Spring 2024 (50%), Spring 2025 (50%)
PHD 1435	Health Promotion and Behavioral Sciences Doctoral and Post-doctoral Research Seminar (Primary or Co-Instructor), UTHealth Houston School of Public Health. Summer 2021 (50%), Fall 2022 (50%), Spring 2023 (75%), Fall 2023 (100%), Spring 2024 (50%), Spring 2025 (50%)
PHWM/D 1120	Program Evaluation (Primary or Co-Instructor), UTHealth Houston School of Public Health. Summer 2022 (75%), Summer 2023 (100%)

Regular Guest Lecturer

PHM/D 1433	Research Seminar in Health Promotion and Behavioral Sciences (Guest Lecturer), UTHealth Houston School of Public Health. Fall 2021, Spring 2022, Fall 2022, Spring 2023, Fall 2023, Spring 2024
CTM 5207	Introduction to Patient-centered Outcomes Research (Guest Lecturer), University of Texas Southwestern Medical Center. Spring 2018, Spring 2019
CTM 5301	Clinical Research Design & Analysis (Guest Lecturer), University of Texas Southwestern Medical Center. Fall 2017, Fall 2018, Fall 2019.

PROFESSIONAL SERVICE

Editorial Service

2023 – present	Senior Editor, Cancer Epidemiology, Biomarkers & Prevention
2023 – 2024	Editor (with Swati Patel, MD; Peter Liang, MD, MPH; and Jennifer Weiss, MD), Special Issue on Disparities in Early-onset Colorectal Cancer, <i>Frontiers in Oncology</i>
2018 – present	Editorial Board, <i>Gastroenterology</i>

Ad-hoc reviewer for:

Cancer; Pharmacoepidemiology and Drug Safety; Cancer Epidemiology, Biomarkers & Prevention; Journal of the National Cancer Institute; Breast Cancer Research and Treatment; Journal of Clinical Oncology; British Journal of Cancer; BMC Cancer; Medical Care; Cancer Causes & Control; Cancer Medicine; Annals of Epidemiology; International Journal of Cancer; Gastroenterology; Clinical Gastroenterology and Hepatology; American Journal of Preventive Medicine; Gut; Epidemiology; JNCI Cancer Spectrum; Paediatric and Perinatal Epidemiology

National and International Grant Review Panels

2023	Ad-hoc reviewer, Cancer Health Equity Research Centers at Minority-Serving Institutions, American Cancer Society
2022	Ad-hoc reviewer, Cancer Health Equity Research Centers at Minority-Serving Institutions, American Cancer Society
2022	Ad-hoc reviewer, Women's Health Research at Yale, Yale University School of Medicine
2021	Ad-hoc reviewer, Cancer Health Equity Research Centers at Minority-Serving Institutions, American Cancer Society
2017	Ad-hoc reviewer, Emerging Investigator Awards for Health, Health Research Board

Research and Advisory Committees

2024 – present	Chair, Advisory Committee to the Texas Cancer Registry
2022 – 2024	Vice Chair, Advisory Committee to the Texas Cancer Registry
2021 – present	Member, Advisory Committee to the Texas Cancer Registry
2021 – 2022	Member, Screening Task Force, American Gastroenterological Association
2020 – 2021	Member, Colorectal Cancer Screening, National Comprehensive Cancer Network
2019 – present	Member, Medical Advisory Board, Fight Colorectal Cancer

INVITED SPEAKING ENGAGEMENTS

International (listed chronologically)

1. Invited speaker (invited by Andrew Chan, MD, MPH), “Early Onset Colorectal Cancer,” Clinical Symposium at Digestive Disease Week (DDW) 2020, Chicago, IL. May 2020 (cancelled due to COVID-19).
2. Invited speaker (invited by planning committee), “Earlier life exposures: maternal obesity and gestational growth,” NIH Think Tank on Early-Onset Colorectal Cancer, Virtual. September 2020.
3. Invited speaker (invited by Cathy Eng, MD), “Exploring the Increasing Recognition of Colorectal Cancer in Young Adult Populations,” 2020 Gastrointestinal Oncology Conference, International Society of Gastrointestinal Oncology, Virtual. October 2020.
4. Invited speaker (invited by Jose Perea Garcia, MD, PhD), “Epidemiology of early-onset colorectal cancer.” Collaborative Group of the Americas on Inherited Gastrointestinal Cancer, Virtual. November 2021.
5. Invited speaker (invited by Elena Stoffel, MD), “Shifting epidemiology of colorectal cancer worldwide.” Digestive Disease Week (DDW) 2022, San Diego, CA. May 2022.
6. Invited speaker (invited by Anjee Davis, MPA), “An update on the etiology and burden of early-age-onset colorectal cancer.” Fight CRC at Digestive Disease Week (DDW) 2022, San Diego, CA. May 2022.
7. Invited speaker (invited by Uri Ladabaum, MD), “Fight CRC: integrating stakeholders with research initiatives in early-onset colorectal cancer.” Colorectal Cancer Screening Committee of the World Endoscopy Organization, San Diego, CA. May 2022.
8. Invited speaker (invited by Giulia Martina Cavestro, MD, PhD), “What is the global epidemiology and age cut-off to define early-onset colorectal cancer.” Delphi Initiative Recommendations on Early-onset Colorectal Cancer (DIRECt): The Path to Improve Diagnosis and Clinical Management. San Raffaele Scientific Institute, Milan, Italy. September 2022.
9. Invited speaker (invited by Rhonda Souza, MD and Samir Gupta, MD), “45 is the new 50, and 50 is the new 55: is an epidemiologic tidal wave of colorectal cancer coming?” Digestive Disease Week (DDW) 2023, Chicago, IL. May 2023.
10. Moderator (with Douglas Morgan, MD), “Evolving Epidemiology of GI Cancers.” Digestive Disease Week (DDW) 2023, Chicago, IL. May 2023.
11. Moderator (with Swati Patel, MD), “Early-onset GI cancers: Risk Factors, Screening and Disparities.” Digestive Disease Week (DDW) 2024, Washington, DC. May 2024.

National (listed chronologically)

1. Invited speaker (invited by Dennis Ahnen, MD), "Advancing the science of early-onset CRC: key epidemiologic questions," Early Age Onset Colorectal Cancer Summit, National Colorectal Cancer Roundtable, Bethesda, MD. December 2017.
2. Invited speaker (selected by planning committee), "Small grants with big impacts: research from five new investigators," 2018 AcademyHealth Annual Research Meeting, Seattle, WA. June 2018.
3. Invited speaker (invited by Dennis Ahnen, MD), "Early-onset colorectal cancer: how can epidemiology help?" Early Age Onset Workshop, Fight Colorectal Cancer (by invitation only), Denver, CO. February 2019.
4. Invited speaker (invited by Shobha Srinivasan, PhD), "Colorectal cancer mortality along the U.S.-Mexico border," 12th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, San Francisco, CA. September 2019.
5. Invited speaker (selected by planning committee), "Early life exposures and risk of young-onset colorectal cancer," New Investigators Workshop, National Cancer Institute, Rockville, MD. November 2019.
6. Invited speaker (invited by Susan Peterson, PhD), "Emerging issues, challenges, and changing epidemiology of EAO-CRC," Early Age Onset Colorectal Cancer Summit, New York, NY. April 2020 (cancelled due to COVID-19).
7. Invited speaker (invited by Frank Berger, MD), "Workshop C: Early Onset Colorectal Cancer," 2020 Annual Meeting of the Southeastern Colorectal Cancer Consortium, Louisville, KY. June 2020 (cancelled due to COVID-19).
8. Invited speaker (invited by Terrence Barret, MD), "Epidemiology and potential mechanisms for the rising tide of early-onset colorectal in the U.S." Division of Digestive Diseases and Nutrition, University of Kentucky, Virtual. February 2021.
9. Invited speaker (invited by Anjee Davis, MPA), "Colorectal cancer screening trends in the U.S." Fight Colorectal Cancer, Virtual Webinar, Virtual. October 2020.
10. Invited speaker (invited by Stephen Gruber, MD), "The big early life story and what it means for colorectal cancer." Early Age Onset Colorectal Cancer Summit, Colon Cancer Foundation, Virtual. May 2021.
11. Invited speaker (invited by Jiyoung Ahn, PhD; Robert Coffey, MD; Scott Kopetz, MD, PhD), "Early-onset colorectal cancer: what have we learned and where do we go from here?" 2021 AACR Special Conference on Colorectal Cancer, Virtual. October 2021.
12. Invited speaker (invited by Paul Schroy, MD), "What is the cause of the rising incidence of early-age-onset colorectal cancer?" 2021 National Colorectal Cancer Roundtable Annual Meeting, Virtual. November 2021
13. Invited speaker (invited by Kenneth Tercyak, PhD), "Colorectal cancer in young adults: clues from early life." Lombardi Comprehensive Cancer Center, Georgetown University, Virtual. July 2022.
14. Invited speaker (invited by Ahmedin Jemal, DVM, PhD), "Colorectal cancer screening and risk factors: where are we headed?" American Cancer Society, Virtual. September 2022.
15. Invited speaker (invited by Lorna Thorpe, PhD), "Pregnancy and cancer in young adults: from risk

to outcomes." Department of Population Health, NYU Langone School of Medicine, Virtual. December 2022.

16. Invited speaker (invited by Alvaro Alonso, PhD, MD), "Pregnancy-related links to cancer diagnosed in adolescents and young adults." Department of Epidemiology, Rollins School of Public Health, Emory University, Virtual. June 2023.
17. Invited speaker (invited by Greg Armstrong, MD), "Multi-generational approaches to studying cancers in adolescents and young adults." Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN. June 2023.
18. Invited speaker (invited by Tara Henderson, MD), "Pregnancy and cancer in adolescents and young adults." Department of Pediatrics, University of Chicago, Chicago, IL, July 2023.
19. Invited speaker (invited by Benjamin Weinberg, MD), "Identifying top suspects for early-onset GI cancers." Early-onset GI Cancer Think Tank, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. November 2023.
20. Session Chair, "Epidemiology and Prevention of GI Cancers." 14th Annual Ruesch Center Symposium, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. November 2023.
21. Invited speaker (invited by John Marshall, MD), "Early-onset GI cancers: when obesity can't explain it all." 14th Annual Ruesch Center Symposium, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. November 2023.
22. Moderator (with Cathy Eng, MD), "Track 1: Research Opportunities for Biology and Etiology." Early-age Onset Colorectal Cancer Think Tank, Fight Colorectal Cancer, Nashville, TN. December 2023.
23. Invited speaker (invited by Cathy Eng, MD), "Reproductive outcomes and fertility in early-onset colorectal cancer." Early-Age Onset Colorectal Cancer Summit, Colon Cancer Foundation, Nashville, TN. February 2024.
24. Wilmott Visiting Professor (selected by GI fellows), "Early-onset colorectal cancer and clues from early life. Division of Gastroenterology and Hepatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania. Philadelphia, PA. June 2024.
25. Invited speaker (invited by Heather Hampel), "Epidemiology of early-onset colorectal cancer: an update and new perspective." Western Colorectal Cancer Consortium Conference, Davis, CA. September 2024.
26. Invited speaker, "Epidemiology of early-onset colorectal cancer: progress and next steps." National Colorectal Cancer Roundtable Annual Meeting, Fort Worth, TX. November 2024.

Local (Texas and North Carolina; listed chronologically)

1. Invited speaker, "Racial disparities in the receipt of adjuvant chemotherapy among stage III colon cancer patients," Gastrointestinal Epidemiology Seminar, University of North Carolina at Chapel Hill, Chapel Hill, NC. October 2014.
2. Invited speaker, "Rising incidence of esophageal adenocarcinoma: an age-period-cohort analysis," Cancer Epidemiology Seminar, University of North Carolina at Chapel Hill, Chapel Hill, NC. November 2014.

3. Invited speaker, "Patterns of repeat and surveillance colonoscopy use," Gastrointestinal Epidemiology Seminar, University of North Carolina at Chapel Hill, Chapel Hill, NC. March 2015.
4. Invited speaker, "Epidemiology and colorectal cancer health services," Gastrointestinal Epidemiology Seminar, University of North Carolina at Chapel Hill, Chapel Hill, NC. November 2015.
5. Invited speaker, "Using epidemiology to improve cancer health services across the colorectal cancer care continuum," Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX. December 2015.
6. Invited speaker, "Using epidemiology to improve cancer health services across the colorectal cancer care continuum," Department of Health Services Research, University of Texas M.D. Anderson Cancer Center, Houston, TX. January 2016.
7. Invited speaker, "Polypharmacy and patterns of prescription medication use among cancer survivors," Translational Science Form, University of Texas Southwestern Medical Center, Dallas, TX. December 2017.
8. Invited speaker, "Tamoxifen and the Road to R01," Clinical Scholars Retreat, University of Texas Southwestern Medical Center, Dallas, TX. March 2018.
9. Invited speaker, "Polypharmacy and patterns of prescription medication use among cancer survivors," Department of Pediatrics Grand Rounds, University of Texas Southwestern Medical Center, Dallas, TX. April 2018.
10. Invited speaker, "Early life exposures and risk of young-onset colorectal cancer," Clinical Scholars Retreat, University of Texas Southwestern Medical Center, Dallas, TX. October 2018.
11. Invited speaker (invited by Paul Scheet, PhD), "Colorectal cancer: the old, the young, and the underscreened," Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX. December 2019.
12. Invited speaker (invited by Kayo Fujimoto, PhD), "A life course approach to understand the increasing burden of cancer in young adults." UTHealth Houston School of Public Health, Houston, TX. October 2020.
13. Invited speaker, "Risk factors for early-onset colorectal cancer (hint: it's not bacon)." Gastrointestinal Epidemiology Seminar, University of North Carolina at Chapel Hill, Virtual. February 2021.
14. Invited speaker, "Trends and risk factors for early-onset colorectal cancer." Sixth Annual Southeastern Colorectal Cancer Consortium Conference, Irving, TX. June 2022.
15. Invited speaker (invited by Wenyi Wang, PhD), "Early life: an important window of susceptibility for colorectal cancer." CRC Integromics Group, MD Anderson Cancer Center, Houston, TX. March 2022.
16. Invited speaker (invited by Natalie Archer, PhD), "Birth defects in offspring of adolescents and young adults diagnosed with cancer." Texas Cancer Registry, Texas Department of State Health Services, Austin, TX. October 2023.
17. Invited speaker (invited by Hashem El-Serag, MD), "Early life exposures and HCC." Fourth Annual TeCH HCC Symposium, Baylor College of Medicine, Houston, TX. August 2024.
18. Invited speaker, "Increasing rates of GI cancer and clues from early life." Gastrointestinal

INTERNAL INSTITUTIONAL SERVICE

2024—present	Co-Chair, Admissions Committee, Department of Health Promotion & Behavioral Sciences, UTHealth Houston School of Public Health
2024	Co-Leader, Preliminary Exam Bootcamp (data analysis section), Department of Health Promotion & Behavioral Sciences, UTHealth Houston School of Public
2024—present	Faculty Mentor, Research Training in Gastroenterology Program (T32DK083266), Baylor College of Medicine
2023—present	Faculty Mentor, TL1 Program, Center for Clinical and Translational Sciences (UL1TR003167), UTHealth Houston
2023—present	Internal Advisory Board, Cancer Prevention and Control Training Program (T32CA057712), UTHealth Houston School of Public Health
2022, 2023	Faculty Search Committee, UTHealth School of Public Health (five open rank positions across multiple departments and campuses)
2022—present	Faculty Mentor, Cancer Prevention and Control Training Program (T32CA057712), UTHealth Houston School of Public Health
2021—present	Member, Admissions Committee, Department of Health Promotion & Behavioral Sciences, UTHealth Houston School of Public Health
2021—present	Faculty Mentor, Gastroenterology and Hepatology Training Program (T32DK007745), University of Texas Southwestern Medical Center
2021—present	Grader, Preliminary Exam (data analysis section), Department of Health Promotion and Behavioral Sciences, UTHealth Houston School of Public Health
2020	Community-Engaged Research Pilot Review Committee, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
2017, 2018	Community Engagement Pilot Review Committee, Clinical and Translational Science Award Program, University of Texas Southwestern Medical Center

PRESS AND MEDIA (LISTED CHRONOLOGICALLY)

1. “Race disparity in colon cancer treatment reemerges in 2010.” Frontline Medical News. July 6, 2015. <http://www.pm360online.com/race-disparity-in-colon-cancer-treatment-reemerges-in-2010/>.
2. “Differences in colon cancer chemotherapy treatment among African-American and white patients.” Epidemiology News and Reports, UNC Gillings School of Public Health. July 14, 2015. <http://sph.unc.edu/sph-news/differences-in-colon-cancer-chemotherapy-treatment-among-african-american-and-white-patients/>.
3. “Blacks may be less likely to get chemo for advanced colon cancer.” Reuters Health. July 16, 2015. <http://www.reuters.com/article/2015/07/16/us-health-racedisparities-colon-cancer-idUSKCN0PQ1MG20150716>.
4. “UNC study finds differences in colon cancer chemo treatment among African-Americans, whites.” Association of Schools and Programs of Public Health (ASPPH). July 16, 2015.

http://www.aspph.org/unc-study-finds-differences-in-colon-cancer-chemo-treatment-among-african-americans-whites/.

5. "Racial, insurance disparities influence chemotherapy receipt for colon cancer." HemOnc Today. August 3, 2015. <http://www.healio.com/hematology-oncology/gastrointestinal-cancer/news/online/%7B8d4e445d-5dcf-4418-a3c3-cbada1c79905%7D/racial-insurance-disparities-influence-chemotherapy-receipt-for-colon-cancer>.
6. "1 in 4 U.S. seniors with cancer has had it before." U.S. News & World Report. November 22, 2017. <https://health.usnews.com/health-care/articles/2017-11-22/1-in-4-us-seniors-with-cancer-has-had-it-before>.
7. "Researchers question exclusion of people with prior cancer history from clinical trials." The Medical News. November 23, 2017. <https://www.news-medical.net/news/20171122/Researchers-question-exclusion-of-people-with-prior-cancer-history-from-clinical-trials.aspx>.
8. "New cancers common in cancer survivors." OnMedica. November 23, 2017. <http://www.onmedica.com/newsArticle.aspx?id=8b264804-6dc3-4e3b-a1b4-d58432d96ea3>
9. "Up to one-third of cancer patients have previously had the disease." United Press International. November 22, 2017. https://www.upi.com/Health_News/2017/11/22/Up-to-one-third-of-cancer-patients-have-previously-had-the-disease/2021511381619/
10. "1 in 4 U.S. seniors with cancer has had it before." MedlinePlus. November 22, 2017. https://medlineplus.gov/news/fullstory_169917.html
11. "Researchers question excluding cancer survivors from clinical trials." D Magazine. November 23, 2017. <http://healthcare.dmagazine.com/2017/11/23/researchers-question-excluding-cancer-survivors-from-clinical-trials/>
12. "Study questions exclusion of cancer survivors from trials." Newswise. November 22, 2017. <http://www.newswise.com/articles/view/685656/?sc=rsla>
13. "Prevalence of secondary cancers underscores need for trial inclusion." HemOnc Today (Healio). November 22, 2017. <https://www.healio.com/hematology-oncology/prostate-cancer/news/in-the-journals/%7B48ce8455-5fa1-411f-8a16-59d27cb0c697%7D/prevalence-of-secondary-cancers-underscores-need-for-trial-inclusion>.
14. "Second cancers common in survivors, especially older adults." Medscape. November 22, 2017. <https://www.medscape.com/viewarticle/889062>.
15. "1 in 4 U.S. seniors with cancer has had it before." WebMD. November 24, 2017. <https://www.webmd.com/cancer/news/20171122/1-in-4-us-seniors-with-cancer-has-had-it-before>.
16. "High incidence of prior cancer in patients newly diagnosed with cancer." medwireNews. November 27, 2017. <https://www.medwirenews.com/oncology/high-incidence-of-prior-cancer-in-patients-newly-diagnosed-with-/15257098>.
17. "When cancer strikes twice." New York Times. December 26, 2017. https://www.nytimes.com/2017/12/25/well/when-cancer-strikes-twice.html?_r=0.
18. "Cancer survivors more likely to be prescribed multiple medications." HemOnc Today. May 8, 2018. <https://www.healio.com/hematology-oncology/practice-management/news/in-the-journals/%7B8aa6a277-a322-4905-91f6-c1fd4776b45f%7D/cancer-survivors-more-likely-to-be-prescribed-multiple-medications>.
19. "Young-onset CRC uptick driven by more rectal cancers among whites." Healio Gastroenterology. December 7, 2018. <https://www.healio.com/gastroenterology/oncology/>

news/online/%7Bb2aaaddb-445e-46d8-86e3-528940b85cae%7D/young-onset-crc-uptick-driven-by-more-rectal-cancers-among-whites

- 20. "Drug used during pregnancy may increase cancer risk in mother's adult children." Newswise. March 17, 2021. <https://www.newswise.com/articles/drug-used-during-pregnancy-may-increase-cancer-risk-in-mother-s-adult-children>
- 21. "Drug used to prevent miscarriages may increase cancer risk of grown children." Philly Voice. March 23, 2021. <https://www.phillyvoice.com/makena-cancer-risk-ohpc-preterm-birth-drug/>
- 22. "Drug used to prevent miscarriages may be upping cancer rates decades later." U.S. News & World Report. March 24, 2021. <https://www.usnews.com/news/health-news/articles/2021-03-24/drug-used-to-prevent-miscarriages-may-be-upping-cancer-rates-decades-later>
- 23. "Blacks, Hispanics, impoverished people have worse survival rates among teens, adults under 40 with cancer." Newswise. April 22, 2021. <https://www.newswise.com/articles/blacks-hispanics-impoveryed-have-worse-survival-rates-among-teens-adults-under-40-with-cancer>
- 24. "Race, neighborhood poverty, insurance associated with higher mortality in people under 40 with cancer." News-Medical.Net. April 22, 2021. <https://www.news-medical.net/news/20210422/Race-neighborhood-poverty-insurance-associated-with-higher-mortality-in-people-under-40-with-cancer.aspx>
- 25. "When cancer strikes those under 40, race matters." U.S. News & World Report. April 28, 2021. <https://www.usnews.com/news/health-news/articles/2021-04-28/when-cancer-strikes-those-under-40-race-matters>
- 26. "For young Texans, race is a stronger predictor of cancer survival than insurance status." Texas Standard. April 28, 2021. <https://www.texasstandard.org/stories/for-young-texans-race-is-a-stronger-predictor-of-cancer-survival-than-insurance-status/>
- 27. "Mom's obesity during pregnancy linked to colon cancer in offspring." MedPage Today. August 23, 2021. <https://www.medpagetoday.com/obgyn/pregnancy/94179>
- 28. "People whose mothers were overweight at higher risk of bowel cancer, study suggests." The Guardian. August 23, 2021. <https://www.theguardian.com/society/2021/aug/23/people-whose-mothers-were-overweight-at-higher-risk-of-bowel-cancer-study-suggests>
- 29. "Maternal obesity, weight gain increase risk for CRC among adult offspring." Healio Gastroenterology. August 24, 2021. <https://www.healio.com/news/gastroenterology/20210824/maternal-obesity-weight-gain-increase-risk-for-crc-among-adult-offspring>
- 30. "Study examines link between in utero events and risk of colorectal cancer in adult offspring." The ASCO Post. September 1, 2021. <https://ascopost.com/news/september-2021/study-examines-link-between-in-utero-events-and-risk-of-colorectal-cancer-in-adult-offspring/>
- 31. "Maternal obesity may up CRC risk in adult offspring." Cancer Therapy Advisor. August 30, 2021. <https://www.cancertherapyadvisor.com/home/cancer-topics/gastrointestinal-cancers/maternal-obesity-may-up-crc-risk-in-adult-offspring/>
- 32. "Maternal obesity linked to higher risk of colorectal cancer in adult offspring." American Association for the Advancement of Science (AAAS). August 24, 2021. <https://www.eurekalert.org/news-releases/926656>
- 33. "Maternal obesity linked to higher risk of colorectal cancer in adult offspring." Newswise. August 26, 2021. <https://www.newswise.com/articles/maternal-obesity-during-pregnancy-linked-to-higher-risk-of-colorectal-cancer-in-adult-offspring>

34. "Maternal obesity during pregnancy may heighten the risk of colorectal cancer in adult offspring." News Medical Life Sciences. August 27, 2021. <https://www.news-medical.net/news/20210827/Maternal-obesity-during-pregnancy-may-heighten-the-risk-of-colorectal-cancer-in-adult-offspring.aspx>
35. "Maternal obesity tied to increased risk of colorectal cancer in offspring." Reuters/Medscape. August 26, 2021. <https://www.medscape.com/viewarticle/957263?src=>
36. "Maternal health may play a big role in who gets colorectal cancer." KPRC-TV Houston. September 10, 2021. <https://www.click2houston.com/news/local/2021/09/11/maternal-health-may-play-a-big-role-in-who-gets-colorectal-cancer/>
37. "Study shows dramatic decline in effectiveness of all three COVID-19 vaccines over time." Los Angeles Times. November 4, 2021. <https://www.latimes.com/science/story/2021-11-04/study-shows-dramatic-decline-in-effectiveness-of-covid-19-vaccines>
38. "Pfizer-BioNTech expected to seek authorization for coronavirus booster for people 18 and older." Washington Post. November 9, 2021. <https://www.washingtonpost.com/health/2021/11/08/pfizer-biontech-coronavirus-booster-authorization-18-and-older/>
39. "Drug used to prevent miscarriage increases risk of cancer in offspring." Science Daily. November 9, 2021. <https://www.sciencedaily.com/releases/2021/11/211109120334.htm>
40. "Colorectal cancer rates rising in people aged 50 to 54 years." Medscape. November 11, 2021. <https://www.medscape.com/viewarticle/962769>
41. "Drug used to prevent miscarriage may raise lifetime cancer risk in offspring." U.S. News & World Report. November 15, 2021. <https://www.usnews.com/news/health-news/articles/2021-11-15/drug-used-to-prevent-miscarriage-may-raise-lifetime-cancer-risk-in-offspring>
42. "Preterm birth drug tied to cancer risk in those exposed in utero." Medpage Today. November 16, 2021. <https://www.medpagetoday.com/obgyn/pregnancy/95623>
43. "The colon cancer conundrum." Scientific American. December 1, 2021; S12. <https://www.scientificamerican.com/article/the-colon-cancer-conundrum/>
44. "A drug for pregnant women doesn't work, according to the FDA. A company is selling it anyway." Los Angeles Times. February 17, 2022. <https://www.latimes.com/business/story/2022-02-17/makena-covis-premature-birth-pregnant-womens-health>
45. "FDA should pull ineffective pregnancy drug Makena until we know it works." Los Angeles Times. February 24, 2022. <https://www.latimes.com/opinion/story/2022-02-24/editorial-does-this-drug-work-stop-selling-it-until-we-know>
46. "Organized CRC screening programs crucial for increasing adherence." Gastroenterology & Endoscopy News. July 25, 2022. <https://www.gastroendonews.com/Functional-GI-Disorders/Article/07-22/CRC-Screening-Colorectal-Cancer-Adherence/67419>
47. "Colorectal cancer screening prevalence remains low among younger adults." HemOnc Today. June 29, 2022. <https://www.healio.com/news/hematology-oncology/20220629/colorectal-cancer-screening-prevalence-remains-low-among-younger-adults>
48. "CRC in middle age linked to morning sickness pill from '60s, '70s." Medscape. March 17, 2023. <https://www.medscape.com/viewarticle/989787>
49. "Q&A: In utero exposure to Bendectin linked to increased risk for CRC in adult offspring." Heilio Gastroenterology. March 24, 2023. <https://www.heilio.com/news/gastroenterology/20230323/qa->

in-utero-exposure-to-bendectin-linked-to-increased-risk-for-crc-in-adult-offspring

- 50. "Shifting trends in CRC demographics, severity prove you are 'not too young to have cancer'." Healio Gastroenterology. May 22, 2023. <https://www.healio.com/news/gastroenterology/20230516/shifting-trends-in-crc-demographics-severity-prove-you-are-not-too-young-to-have-cancer>
- 51. "Prenatal exposure to antinausea drug associated with increased colorectal cancer risk." Healio Hematology/Oncology. June 1, 2023. <https://www.healio.com/news/hematology-oncology/20230601/prenatal-exposure-to-antinausea-drug-associated-with-increased-colorectal-cancer-risk>
- 52. "Number of cancer survivors diagnosed with new malignancies increases 15%." Healio Hematology/Oncology. June 15, 2023. <https://www.healio.com/news/hematology-oncology/20230615/number-of-cancer-survivors-diagnosed-with-new-malignancies-increases-15>
- 53. "Birth defects more common in babies born to moms who've had cancer. U.S. News & World Report. October 10, 2023. <https://www.usnews.com/news/health-news/articles/2023-10-10/birth-defects-more-common-in-babies-born-to-moms-who've-had-cancer>
- 54. "Birth defects higher in offspring of teen, young adult women with cancer history." HealthDay. November 3, 2023. <https://www.healthday.com/healthpro-news/birth-defects-higher-in-offspring-of-teen-young-adult-women-with-cancer-history>
- 55. "Colorectal cancer is rising among younger adults. Some states want to boost awareness." Stateline. March 6, 2024. <https://stateline.org/2024/03/06/colorectal-cancer-is-rising-among-younger-adults-some-states-want-to-boost-awareness/>
- 56. "Why are so many young people getting cancer? What the data say." Nature. March 13, 2024. <https://www.nature.com/articles/d41586-024-00720-6>
- 57. "More young people than ever will get colorectal cancer this year." New York Times. March 27, 2024. <https://www.nytimes.com/2024/03/27/health/colon-cancer-symptoms-treatment.html>
- 58. "What's causing cancer rates to rise in Gen X and Millennials?" Cancer Straight Talk Podcast. September 12, 2024. <https://www.mskcc.org/videos/whats-causing-cancer-rates-to-rise-in-gen-x-and-millennials>